Nifty Pharma

DR REDDY’S: US FDA ISSUES FORM 483 WITH TWO OBSERVATIONS TO DR. REDDY’S NEW YORK FACILITY

AUROBINDO PHARMA: CO TO CONSIDER Q4 RESULT ON MAY 26

SUN PHARMA: CO ANNOUNCES FDA APPROVAL OF NEXT GENERATION BLU-U® BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATOR FOR ACTINIC KERATOSIS

JB CHEMICALS & PHARMA: CO IS RAISING ITS OPERATING MARGIN GUIDANCE FOR THE THIRD YEAR IN A ROW, WITH EBITDA MARGINS EXPECTED TO BE IN THE RANGE OF 27% TO 29% -- CO IS TARGETING A RUN RATE OF CLOSE TO 140,000 UNITS PER MONTH BY THE END OF H1 - CONCALL UPDATE

LUPIN: CO BELIEVES THAT REDUCING PRICING IN THE US WOULD HAVE A SIGNIFICANT IMPACT ON INNOVATION IN THE PHARMACEUTICAL INDUSTRY, AS THE US MARKET FUNDS THE MAJORITY OF INNOVATION IN THE INDUSTRY - CONCALL UPDATE

LUPIN: COS EBITDA MARGINS ARE IN LINE WITH ITS PEER GROUP, AND ARE EXPECTED TO CONTINUE IMPROVING AS NEW ADJACENCIES GROW IN SIZE AND CONTRIBUTE TO PROFITS - CONCALL UPDATE

LUPIN: CO EXPECTS TO GROW OVER USD 250M A QUARTER -- CO AIMS TO GROW AT DOUBLE DIGITS, NOT JUST FOR THE NEXT YEAR, BUT SUSTAINABLY -- CO TARGETS GROWTH OF 20%, 30% AHEAD OF THE MARKET, WHICH IS EXPECTED TO GROW AT 6%, 7%, OR 8% - CONCALL UPDATE

BIOCON: CO UNIT BIOCON PHARMA HAS RECEIVED APPROVAL FOR ITS ANDA FOR RIVAROXABAN TABLETS USP FROM THE US FDA, FOR STRENGTHS OF 2.5 MG, 10 MG, 15 MG AND 20 MG

ALKEM LABS: CO SAYS ENZENE DETECTED A CYBER SECURITY INCIDENT ON ITS US SUBSIDIARY; INCIDENT RESULTED IN A FRAUDULENT TRANSFER OF FUNDS -- CO SAYS BUSINESS EMAIL IDS OF CERTAIN EMPLOYEES AT THE US SUBSIDIARY WERE COMPROMISED

LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR RIVAROXABAN -- US SALES USD 8B

LUPIN: CO RECOMMENDED A DIVIDEND OF 12 RUPEES PER EQUITY SHARE

LUPIN: Q4 EBITDA 13.21B RUPEES VS 9.97B (YOY) -- Q4 EBITDA MARGIN 23.31% VS 20.09% (YOY)

LUPIN: Q4 REVENUE 56.67B RUPEES VS 49.6B (YOY)

LUPIN: Q4 CONS NET PROFIT 7.73B RUPEES VS 3.59B (YOY); 8.55B (QOQ)

J.B.CHEMICALS & PHARMACEUTICALS: CO HAS RECOMMENDED A DIVIDEND OF 7 RUPEES PER EQUITY SHARE

J.B.CHEMICALS & PHARMACEUTICALS: Q4 EBITDA 2.3B RUPEES VS 1.98B (YOY) -- Q4 EBITDA MARGIN 23.85% VS 22.99% (YOY)

J.B.CHEMICALS & PHARMACEUTICALS: Q4 CONS NET PROFIT 1.46B RUPEES VS 1.26B (YOY); 1.6B (QOQ) -- Q4 REVENUE 9.5B RUPEES VS 8.6B (YOY)

ZYDUS LIFESCIENCES: CO RECEIVES EIR FOR THE AMBERNATH API MANUFACTURING FACILITY

TORRENT PHARMA: CO TO CONSIDER Q4 RESULT ON MAY 20

TORRENT PHARMA: BOARD MEETING ON MAY 20 TO CONSIDER FUNDRAISING

AUROBINDO PHARMA: CO UNIT CURATEQ BIOLOGICS RECEIVES APPROVAL FOR BIOSIMILAR ZEFYLTI FROM UKS MHRA

CIPLA: US BUSINESS REVENUE AT USD 221M VS EST USD 220M

CIPLA: Q4 REVENUE 67.3B RUPEES VS 62B (YOY); EST 67B

CIPLA: Q4 EBITDA 15.4B RUPEES VS 13.2B (YOY); EST 15.82B -- Q4 EBITDA MARGIN 22.85% VS 21.35% (YOY); EST 24%

CIPLA: CO DECLARES DIVIDEND OF RUPEES 16 PER SHARE, INCLUDING RUPEES 3 SPECIAL DIVIDEND

CIPLA: Q4 CONS NET PROFIT 12.2B RUPEES VS 9.4B (YOY); EST 10.52B

LUPIN: CO LAUNCHES TOLVAPTAN TABLETS IN THE U.S. WITH 180-DAY EXCLUSIVITY -- THIS TABLETS HAS US SALES OF USD 1.5B

SUNPHARMA: CO TO CONSIDER Q4 RESULT ON MAY 22

GLENMARK PHARMA: CO TO CONSIDER Q4 RESULT ON MAY 23

NATCO PHARMA: CO TO CONSIDER Q4 RESULT ON MAY 28

Sun Pharmaceutical Industries Ltd.: Rs. 42.57 Crores NSE Block Trade; for ~ 255,499 Shares, at Rs. 1666.20

BIOCON: COS CHAIRPERSON SAYS EXPECT US PHARMA TARIFFS TO BE FAIRLY LOW

DR REDDYS LABS: CO BELIEVES THAT DOUBLE-DIGIT GROWTH IN FY26 IS POSSIBLE WHILE MAINTAINING MARGINS -- CO ANTICIPATES HIGH DOUBLE-DIGIT GROWTH IN INDIA NEXT YEAR, DRIVEN BY NEW PRODUCTS, INNOVATION, AND ADDRESSING UNDERPERFORMING BIG BRANDS - CONCALL UPDATE

DR REDDYS LABS: CO EXPECTS THE ETR FOR FY26 TO BE SIMILAR TO THE CURRENT FISCAL YEAR -- CO GUIDED FOR DOUBLE-DIGIT SALES GROWTH IN FY26 -- CO EXPECTS TO MAINTAIN EBITDA ROCE OF 25% OR ABOVE IN FY26 - CONCALL UPDATE

BIOCON: CO EXPECTS OPERATING LEVERAGE AND GROSS MARGIN IMPROVEMENT AS NEW LAUNCHES COME IN, WITH INCREMENTAL GROSS MARGIN ON THOSE LAUNCHES BEING HIGHER THAN THE EXISTING BUSINESS - CONCALL UPDATE

GLENMARK PHARMA: CO HAS ANNOUNCED THAT ITS INDORE MANUFACTURING FACILITY HAS BEEN CLASSIFIED AS "OFFICIAL ACTION INDICATED" (OAI) BY THE USFDA FOLLOWING AN EARLIER INSPECTION IN FEBRUARY 2025 -- CO SAYS WILL WORK CLOSELY WITH THE US FDA TO ACHIEVE A FULLY COMPLIANT STATUS

DR. REDDY’S LAB: CO UNIT DR. REDDY’S LABORATORIES SA, SWITZERLAND (DRSA), HAS ESTABLISHED A NEW WHOLLY-OWNED SUBSIDIARY IN VIETNAM NAMED "DR. REDDYS LABORATORIES (VIETNAM) COMPANY LIMITED"

DR.REDDYS LABORATORIES: CO RECOMMENDED A FINAL DIVIDEND OF 8 RUPEES PER EQUITY SHARE

DR.REDDYS LABORATORIES: Q4 EBITDA 19.98B RUPEES VS 18.7B (YOY); EST 21.9B -- Q4 EBITDA MARGIN 23.43% VS 25.74% (YOY); EST 26.5%

DR.REDDYS LABORATORIES: Q4 REVENUE 85.3B RUPEES VS 71.14B (YOY); EST 82.8B

DR.REDDYS LABORATORIES: Q4 CONS NET PROFIT 15.94B RUPEES VS 13.1B (YOY); EST 13.7B - 14.13B (QOQ)

ZYDUS LIFE: CO. RECEIVES FINAL APPROVAL FROM USFDA FOR GLATIRAMER ACETATE INJECTION, THE GENERIC VERSION OF COPAXONE 20 MG/ML, 40 MG/ML, SINGLE-DOSE PREFILLED SYRINGES -- GLATIRAMER ACETATE INJECTION HAD ANNUAL SALES OF USD 719M IN THE USA

BIOCON: CO SAYS IN FY26, WE EXPECT TO SEE A RECOVERY IN API BUSINESS -- CO SAYS FOCUSED ON STRATEGIC EXPANSION OF DIFFERENTIATED GLP-1 PORTFOLIO INTO NEW MARKETS

BIOCON: Q4 EBITDA 10.8B RUPEES VS 9.16B (YOY); EST 9.43B -- Q4 EBITDA MARGIN 24.41% VS 23.38% (YOY); EST 22.6%

BIOCON: Q4 CONS NET PROFIT 3.4B RUPEES VS 1.35B (YOY); EST 1.68B -- Q4 REVENUE 44.2B RUPEES VS 39.2B (YOY); EST 41.69B

MANKIND PHARMA: CO TO CONSIDER Q4 RESULT ON MAY 21

LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR RALTEGRAVIR TABLETS USP, 600 MG -- CO SAYS BEING THE EXCLUSIVE FIRST-TO-FILE, LUPIN IS ELIGIBLE FOR 180-DAY GENERIC EXCLUSIVITY

LUPIN: CO LAUNCHES ESLICARBAZEPINE ACETATE TABLETS IN U.S; ELIGIBLE FOR 180 DAYS OF SHARED GENERIC EXCLUSIVITY -- ESLICARBAZEPINE ACETATE TABLETS (RLD APTIOM®) HAD ESTIMATED ANNUAL SALES OF USD 395 MILLION IN THE U.S. (IQVIA MAT MARCH 2025

SUN PHARMA: CO SAYS JAYASHREE SATAGOPAN APPOINTED AS CFO

GLAND PHARMA: CO TO CONSIDER Q4 RESULT ON MAY 20

GLENMARK PHARMA: ICHNOS GLENMARK INNOVATION (IGI) RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ISB 2001 FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

BIOCON: BIOCON BIOLOGICS SECURES STRONG MARKET ACCESS COVERAGE FOR YESINTEK IN THE UNITED STATES COVERING 100+ MILLION LIVES

DIVIS LABORATORIES LTD.: RS. 60.77 CRORES NSE BLOCK TRADE; FOR ~ 100,045 SHARES, AT RS. 6074.50

DIVIS LABORATORIES LTD.: RS. 88.61 CRORES NSE BLOCK TRADE; FOR ~ 144,937 SHARES, AT RS. 6114.00

AUROBINDO PHARMA: CO SAYS APPELLATE AUTHORITY REJECTS COS APPEAL AGAINST TAX DEMAND ORDER -- TOTAL DISPUTE AMOUNTS TO 70.6M RUPEES

AJANTA PHARMA: Q4 REVENUE 11.7B RUPEES VS 10.54B (YOY)

AJANTA PHARMA: Q4 EBITDA 2.97B RUPEES VS 2.78B (YOY) -- Q4 EBITDA MARGIN 25.38% VS 26.4% (YOY)

AJANTA PHARMA: Q4 CONS NET PROFIT 2.25B RUPEES VS 2B (YOY)

GLAND PHARMA: CO RECEIVES APPROVAL FROM USFDA FOR LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION -- US SALES OF USD 171M FOR THIS DRUG

TORRENT PHARMACEUTICALS LTD.: RS. 156.89 CRORES NSE BLOCK TRADE; FOR ~ 470,302 SHARES, AT RS. 3335.90

ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM USFDA FOR NIACIN EXTENDED-RELEASE TABLETS -- US SALES OF USD 5.5M

LUPIN: CO TO CONSIDER Q4 RESULT ON MAY 14

GLENMARK PHARMA : CO CLAIRIFIES REPORT ABOUT CDSCO FLAGGING DRUGS -- CO SAYS PRODUCTS REFERRED TO IN REPORT SPURIOUS; NOT MADE BY CO

AUROBINDO PHARMA: CO SAYS OPERATIONS PAUSED FOR 20-25 DAYS FOR EQUIPMENT REPLACEMENT -- CO SAYS FIRE CAUSED BY SELF-IGNITION OF COAL

AUROBINDO PHARMA: CO SAYS FIRE INCIDENT AT AUROBINDOS KAKINADA FACILITY; INCIDENT NOT EXPECTED TO IMPACT GROUP FINANCIALS -- SAYS NO INJURIES REPORTED, CORE INFRASTRUCTURE UNAFFECTED

ZYDUS LIFESCIENCES: USFDA CONCLUDES INSPECTION AT DABHASA API UNIT WITH 6 OBSERVATIONS, NONE RELATED TO DATA INTEGRITY

AUROBINDO PHARMA: CO UNIT CURATEQ BIOLOGICS RECEIVES POSITIVE OPINION FROM CHMP FOR DAZUBLYS, A TRASTUZUMAB BIOSIMILAR

BIOCON: BIOCON BIOLOGICS RECEIVES POSITIVE CHMP OPINIONS FOR BIOSIMILAR DENOSUMAB IN EUROPE

ZYDUS LIFESCIENCES: CO TO BUY 75.4% OF SHARE CAPITAL OF AMPLITUDE; PRICE OF €6.25 PER AMPLITUDE SHARE

ZYDUS LIFESCIENCES: CO SIGNS PURCHASE AGREEMENT WITH PAI PARTNERS AND OTHER SHAREHOLDERS TO ACQUIRE A MAJORITY STAKE IN AMPLITUDE SURGICAL SA -- SUBJECT TO FULFILMENT OF CLOSING CONDITIONS, ZYDUS WILL ACQUIRE 85.6% OF SHARE CAPITAL OF AMPLITUDE

LAURUS LABS: GUIDANCE - CO SAYS NO HALT SEEN IN USAID SPENDING SO FAR. EXPECT ARV BUSINESS TO BE STABLE IN FY26 - CONCALL

LAURUS LABS: GUIDANCE - TOPLINE GROWTH SEEN WITH FURTHER IMPROVEMENT IN EBITDA MARGINS -- FURTHER STRENGTHENING OF CDMO BUSINESS, IN DISCUSSION FOR KEY MOLECULES - CONCALL

LAURUS LABS: Q4 REVENUE 17.2B RUPEES VS 14.4B (YOY); EST 16.46B

LAURUS LABS: Q4 EBITDA 4.20B RUPEES VS 2.41B (YOY); EST 3.98B -- Q4 EBITDA MARGIN 24.42% VS 16.82% (YOY); EST 24%

LAURUS LABS: Q4 CONS NET PROFIT 2.34B RUPEES VS 756M (YOY); EST 1.85B

LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR TOLVAPTAN TABLETS -- US SALES OF USD 1.5B

LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR TOLVAPTAN TABLETS -- US SALES OF USD 1.5B

SUN PHARMA: CO AND MOEBIUS MEDICAL ANNOUNCE DUAL PUBLICATIONS ON MM-II’S PHASE 2B CLINICAL TRIAL RESULTS AND MECHANISM OF ACTION IN OSTEOARTHRITIS AND CARTILAGE

BIOCON: CO TO RAISE UP TO 45B RUPEES VIA SECURITIES ISSUANCE -- RAISING OF FUNDS BY WAY OF QUALIFIED INSTITUTIONS PLACEMENT OR ANY OTHER METHOD

AUROBINDO PHARMA: EUGIA PHARMA RECEIVES USFDA APPROVAL FOR DASATINIB TABLETS -- THIS TABLETS HAS US SALES OF USD 1.8B

LUPIN: LUPIN DIAGNOSTICS ACHIEVES NABL ACCREDITATION FOR ALL GREENFIELD LABS -- CO SAYS NOW AMONG INDIAS TOP FULLY ACCREDITED DIAGNOSTIC CHAINS

Sun Pharmaceutical Industries Ltd.: Rs. 15.81 Crores NSE Block Trade; for ~ 90,708 Shares, at Rs. 1742.80

Dr. Reddys Laboratories Ltd.: Rs. 16.11 Crores NSE Block Trade; for ~ 137,711 Shares, at Rs. 1169.80

Glenmark Pharmaceuticals Ltd.: Rs. 28.18 Crores NSE Block Trade; for ~ 208,684 Shares, at Rs. 1350.60

ZYDUS LIFESCIENCES: CO UNIT ZYDUS MEDTECH AND BRAILE BIOMEDICA OF BRAZIL ANNOUNCE GLOBAL LICENSING PACT TO COMMERCIALISE TAVI TECHNOLOGY -- ZYDUS MEDTECH GETS RIGHTS TO MARKET THE INNOVATIVE TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) TECHNOLOGY IN INDIA, EUROPE AND OTHER SELECT MARKETS

LUPIN: CO RECEIVES EIR FROM US FDA FOR NAGPUR FACILITY

ZYDUS LIFE: COWILL CONTINUE TO MARKET MIRABEGRON GENERIC IN US -- EVALUATING LEGAL OPTIONS ON MIRABEGRON GENERIC PATENT CASE 1 - NDTV PROFIT

ZYDUS LIFE: CO ANNOUNCES THE EXECUTION OF UNDERTAKINGS TO TENDER AS PART OF ITS ENVISAGED TENDER OFFER FOR AMPLITUDE SURGICAL SA SHARES

ZYDUS LIFESCIENCES: ZYNEXT VENTURES, THE VENTURE CAPITAL ARM OF THE CO, INVESTS IN CANADA-BASED FELDAN THERAPEUTICS TO DRIVE INNOVATION IN INTRACELLULAR DRUG DELIVERY OF THERAPEUTICS

GLENMARK PHARMA: CO SAYS ACCORDING TO IQVIA SALES DATA FOR THE 12-MONTH PERIOD ENDING FEBRUARY 2025, THE ADDERALL® TABLETS, 5 MG, 10 MG, 15 MG, 20 MG, AND 30 MG MARKET ACHIEVED ANNUAL SALES OF APPROXIMATELY $421.7M

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA TO LAUNCH DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS (MIXED SALTS OF A SINGLE ENTITY AMPHETAMINE PRODUCT), 5 MG, 10 MG, 15 MG, 20 MG AND 30 MG

ZYDUS LIFESCIENCES: US COURT RULES AGAINST ZYDUS IN PATENT LITIGATION -- CO SAYS EVALUATING IMPACT AND LEGAL REMEDIES OF COURT ORDER

LUPIN: CO SAYS US DISTRICT COURT DELAWARE PASSES ORDER IN MYRBETRIQ PATENT CASE -- CO SAYS ASSESSING IMPACT OF US COURT ORDER

LUPIN: CO AND ZYDUS HAS TO WITHDRAW THE DRUG FROM THE MARKET -- COMPANIES WILL ALSO SEE FINANCIAL PENALTY

LUPIN: CO AND ZYDUS HAS TO WITHDRAW THE DRUG FROM THE MARKET -- COMPANIES WILL ALSO SEE FINANCIAL PENALTY

LUPIN: CO AND ZYDUS HAS TO WITHDRAW THE DRUG FROM THE MARKET -- COMPANIES WILL ALSO SEE FINANCIAL PENALTY

ZYDUS LIFE: CO AND LUPIN HAS TO WITHDRAW THE DRUG FROM THE MARKET -- COMPANIES WILL ALSO SEE FINANCIAL PENALTY

LUPIN: CO AND ZYDUS LOST LITIGATION ON MYRBETRIQ IN FC ON PATENT 780

Sun Pharmaceutical Industries Ltd.: Rs. 21.17 Crores NSE Block Trade; for ~ 125,345 Shares, at Rs. 1688.90

DR. REDDY’S: CO CLARIFIES THAT NO COMMENT ON SPECULATED SANOFI LANTUS ACQUISITION; NO MATERIAL EVENT TO DISCLOSE AS OF NOW

LAURUS LABS: INSPECTION CONDUCTED BY THE USFDA AT API MANUFACTURING FACILITY (VISAKHAPATNAM), ANDHRA PRADESH -- CO HAS RECEIVED THE EIR

LAURUS LABS: CO HAS RECEIVED EIR FROM THE USFDA FOR ITS API UNIT-4 FACILITY IN ANDHRA PRADESH FOLLOWING A JANUARY 2025 INSPECTION.

LAURUS LABS: TRUMP ADMINISTRATION WANTS TO NEARLY HALVE STATE DEPT BUDGET - RTRS

ZYDUS LIFESCIENCES: CO HAS CREATED A NEW COMPANY IN FRANCE, CALLED ZYDUS MEDTECH (FRANCE) SAS, TO HANDLE THE PURCHASE OF A LARGE PORTION OF AMPLITUDE SURGICAL SA, FRANCE

AUROBINDO PHARMA: CO’S RALEIGH PLANT RECEIVED 11 PROCEDURAL OBSERVATIONS FROM USFDA POST INSPECTION, WITH NO EXPECTED MATERIAL IMPACT ON OPERATIONS.

LAURUS LABS: VERY BIG JUMP IN EXPORTS FROM INDIA CDMO PHARMA PLAYERS -- EXPORTS AT $53MN, UP 18% YOY, Q4 EXPORTS ALSO HAS JUMPED 60%YOY

DIVIS LAB: VERY BIG JUMP IN EXPORTS FROM INDIA CDMO PHARMA PLAYERS -- EXPORTS AT $85MN, UP 22% YOY, Q4 EXPORTS ALSO HAS JUMPED 23%

Dr. Reddys Laboratories Ltd.: Rs. 41.05 Crores NSE Block Trade; for ~ 365,549 Shares, at Rs. 1122.95

CIPLA: CO HAS RECEIVED FINAL APPROVAL FROM THE USFDA FOR THE ANDA SUBMITTED FOR PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND)

BIOCON: CO UNIT HAS RECEIVED APPROVAL FOR ITS ANDA FOR EVEROLIMUS TABLETS FROM THE US FDA, EVEROLIMUS IS A PRESCRIPTION MEDICATION THAT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS, AND IN KIDNEY AND LIVER TRANSPLANTATION

GRANULES INDIA: CO ANNOUNCES CLOSING OF ACQUISITION OF SENN CHEMICALS, STRENGTHENING CAPABILITIES IN PEPTIDE THERAPEUTICS AND CDMO SERVICES -- CO ENTERS CDMO SPACE WITH SENN ACQUISITION

SUN PHARMA: CO SAYS NO LONGER UNDER COURT ORDER THAT DELAYS OR RESTRICTS CO FROM LAUNCHING LEQSELVI -- CO SAYS WILL DISCLOSE LEQSELVI LAUNCH PLANS IN DUE COURSE OF TIME

SUN PHARMA: CO SAYS U.S. COURT OF APPEALS VACATES PRELIMINARY INJUNCTION ON LEQSELVI -- U.S. COURT OF APPEALS RULED IN FAVOUR OF CO; LITIGATION WITH INCYTE CONTINUES, PRELIMINARY INJUNCTION LIFTED

BIOCON: CO UNIT BIOCON BIOLOGICS ANNOUNCES U.S. FDA APPROVAL FOR JOBEVNE™ , BIOSIMILAR BEVACIZUMAB, EXPANDING ITS ONCOLOGY PORTFOLIO -- CO SAYS IN THE U.S., SALES OF BEVACIZUMAB WERE APPROXIMATELY $2.0B IN 2023

AUROBINDO PHARMA: CO UNIT CURATEQ BIOLOGICS COMPLETES A SUCCESSFUL PHASE 1 PHARMACOKINETICS STUDY OF DENOSUMAB BP16, A PROPOSED BIOSIMILAR TO PROLIA® AND XGEVA®

NATCO PHARMA: CO INTENDS TO LAUNCH RISDIPLAM AFTER CLARITY FROM APPELLATE BENCH, WHICH IS EXPECTED SHORTLY

NATCO PHARMA: ROCHE APPEALS DECISION, APPELLATE BENCH DIRECTS STATUS QUO -- PRICES RISDIPLAM AT 15,900 RUPEES MRP -- CO TO OFFER DISCOUNT ON RISDIPLAM THROUGH PATIENT ACCESS PROGRAMME

NATCO PHARMA: CO SAYS DELHI HIGH COURT DENIES ROCHES INJUNCTION PLEA AGAINST CO -- CO UPDATES ON LEGAL PROCEEDINGS FOR RISDIPLAM LAUNCH IN INDIA

CIPLA: BOARD MEETING ON MAY 13 TO CONSIDER Q4 RESULTS

SUN PHARMA: CO INTRODUCES A NOVEL CLASS OF DRUG, FEXUCLUE(FEXUPRAZAN) IN INDIA FOR TREATMENT OF EROSIVE ESOPHAGITIS

BIOCON: CO HAS APPROVED ISSUANCE OF COMMERCIAL PAPERS UP TO AN AMOUNT NOT EXCEEDING RS. 600 CRORES IN ONE OR MORE TRANCHES ON PRIVATE PLACEMENT BASIS

DIVIS LAB: CLSA SAYS THE RECIPROCAL TARIFF SHOULD BE UP TO 10% FOR INDIAN PHARMA COMPANIES -- INDIA RECEIVES <$50MN FROM CUSTOMS DUTY ON US IMPORTS

DIVIS LAB: CLSA BELIEVE THE RISK OF VERY HIGH TARIFFS TO INDIAN PHARMA COMPANIES IS LOW -- CUSTOMS DUTY ON US PHARMA IMPORTS IN INDIA IS FROM 5-10%

GLAND PHARMA: CO RECEIVES APPROVAL FOR ACETAMINOPHEN INJECTION -- THIS INJECTION HAS US SALES OF USD 55M

LUPIN: CO UNIT LUPIN HEALTHCARE UK ACQUIRES RENASCIENCE PHARMA; ACQUISITION COST GBP 12.3M -- CO SAYS ACQUISITION TO EXTEND LUPINS SPECIALTY PHARMA PORTFOLIO IN UK

BIOCON: CO TO CONSIDER Q4 RESULT ON APRIL 30

JB CHEMICALS: CO APPROVED ACQUISITION OF SHARES OF JAMNAGAR RENEWABLES ONE FOR 70M RUPEES

Lupin Ltd.: Rs. 40.48 Crores NSE Block Trade; for ~ 201,611 Shares, at Rs. 2007.75

BIOCON: BOARD MEETING ON APRIL 4 TO CONSIDER AND APPROVE THE RAISING OF FUNDS THROUGH ISSUANCE OF COMMERCIAL PAPERS (CPS) OR THROUGH ANY OTHER MODE ON PRIVATE PLACEMENT BASIS

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA LAUNCHES VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 750 MG/VIAL, 1.25 G/VIAL AND 1.5 G/VIAL (SINGLE-DOSE VIAL)

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA LAUNCHES VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, (SINGLE-DOSE VIAL) -- THIS DOSE MARKET2 ACHIEVED ANNUAL SALES OF APPROXIMATELY USD 39.3M

LUPIN: CO SAYS TRANSFER OF COS API R&D DIVISION TO LUPIN MANUFACTURING SOLUTIONS

MANKIND PHARMA: CO SAYS NCLT APPROVES AMALGAMATION OF BSV PHARMA WITH BHARAT SERUMS AND VACCINES

MANKIND PHARMA: CO SAYS IT AUTHORITY RAISES ADDITIONAL TAX DEMAND OF 1.83B RUPEES

ZYDUS LIFESCIENCES: CO EXTEND CLOSE OF DEAL WITH STERLING BIOTECH TO SEPTEMBER 30, 2025

ALKEM LABORATORIES: CO SAYS SHARE PURCHASE AGREEMENT EXECUTED BETWEEN ALKEM AND ADROIT BIOMED

IPCA LABORATORIES: CO TO SELL TARAPUR MANUFACTURING FACILITY FOR 369 MILLION RUPEES

DR. REDDYS LAB: BIO-THERA AND DR. REDDYS EXECUTE EXCLUSIVE COMMERCIALIZATION AGREEMENT FOR BAT2206 AND BAT2506 -- BIO-THERA- CO TO MAINTAIN RESPONSIBILITY FOR DEVELOPMENT, MANUFACTURING, SUPPLY OF BAT2206 & BAT2506 -- BIO-THERA- DR. REDDYS WILL RECEIVE EXCLUSIVE COMMERCIAL RIGHTS TO BAT2206 IN COLOMBIA - RTRS

J.B. CHEMICALS & PHARMACEUTICALS LTD.: RS. 1469.17 CRORES NSE BLOCK TRADE; FOR ~ 9,000,614 SHARES, AT RS. 1632.30

DR. REDDY: BIO-THERA AND CO EXECUTE EXCLUSIVE COMMERCIALIZATION AGREEMENT FOR BIOSIMILAR PRODUCT FOR S.E. ASIA - ET NOW

TORRENT PHARMA: CO ISSUES 2B RUPEES COMMERCIAL PAPERS

JB CHEMICALS & PHARMA: BLOCK DEAL ALERT - JB CHEM BOOK LAUNCHED FOR STAKE SALE UP TO 10.2% VIA BLOCK DEALS -- PROMOTER KKR ENTITY - TAU INVESTMENT TO SELL 1.59 CR SHARES -- BLOCK DEAL FLOOR PRICE SET AT RS 1625 PER SHARE -- KOTAK, IIFL BROKER TO DEAL -- TOTAL BLOCK DEAL SIZE AT RS 2575 CRORES - CNBC AWAAZ, CITING SOURCES

SUN PHARMA: CO HAS RECEIVED A COMMUNICATION FROM INVESTEE COMPANY, LYNDRA THERAPEUTICS INC., INFORMING THE CO THAT THEY ARE CEASING OPERATIONS EFFECTIVE MARCH 26, 2025, DUE TO INSUFFICIENT FUNDING TO CONTINUE THEIR BUSINESS ACTIVITIES

TORRENT PHARMA: CO ISSUES 3 BILLION RUPEES COMMERCIAL PAPERS

GRANULES INDIA: CO BOARD APPROVES INTERNAL RESTRUCTURING PLAN FOR US SUBSIDIARIES -- CO SAYS NO CHANGE IN ULTIMATE OWNERSHIP OR BUSINESS NATURE IN US

NATCO PHARMA: DELHI HC REJECTS ROCHES PLEA TO BLOCK CO ON RISDIPLAM PATENT - ET

NATCO PHARMA: DELHI HC REJECTS ROCHES PLEA TO BLOCK NATCO PHARMA ON RISDIPLAM PATENT - ET

GLENMARK PHARMA: USFDA HAS FOUND PROBLEMS AT AN INDIAN FACTORY THAT MAKES GENERIC DRUGS FOR AMERICAN PATIENTS - PROPUBLICA

BIOCON: CO UNIT HAS RECEIVED APPROVAL FROM U.S. FDA FOR ITS ANDA NOREPINEPHRINE BITARTRATE INJECTION USP, SINGLE-DOSE VIAL, NOREPINEPHRINE BITARTRATE INJECTION IS INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH ACUTE HYPOTENSION

DR. REDDYS: CO TO CONSIDER Q4 RESULT ON MAY 9

LUPIN: CO UNIT NANOMI RECEIVES CMO AWARD FOR LIFE SCIENCE LEADERSHIP IN DRUG DELIVERY

MANKIND PHARMA: WEIGHT UPGRADE IN THE FTSE ALL WORLD INDEX INFLOW OF ($16.0 MILLION) 1.3B RUPEES

CIPLA: WEIGHT UPGRADE IN THE FTSE ALL WORLD INDEX INFLOW OF ($30.4 MILLION) 2.6B RUPEES

AJANTA PHARMA: STOCK ADDITION IN THE FTSE ALL WORLD INDEX INFLOW OF ($23.8 MILLION) 2.0B RUPEES

AJANTA PHARMA: CO SAYS ADDING A LIQUID FORMULATION FACILITY AT ITS PITHAMPUR SITE -- CO SAYS INVESTMENT REQUIRED 920M RUPEES FOR EXPANSION

AUROBINDO PHARMA: CO UNIT RECEIVES INSPECTION REPORT CLASSIFYING THE FACILITY AS "VOLUNTARY ACTION INDICATED" (VAI)

DR. REDDYS LABORATORIES: ALVOTECH AND DR. REDDY’S ANNOUNCE FDA ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION FOR AVT03, A PROPOSED BIOSIMILAR TO PROLIA® AND XGEVA® - RTRS

ZYDUS LIFESCIENCES: ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR APALUTAMIDE TABLETS, 60 MG -- APALUTAMIDE TABLETS HAD ANNUAL SALES OF USD 1099.8 MN IN THE UNITED STATES (IQVIA MAT JANUARY 2025)

GRANULES: CO UNIT GRANULES EUROPE HAS BEEN VOLUNTARILY DISSOLVED

LUPIN: CO SAYS SUBSIDIARY LUPINLIFE CONSUMER HEALTHCARE INCORPORATED

CIPLA: COAND FORMOSA SIGN MULTI-REGIONAL LICENSING DEAL FOR CLOBETASOL SUSPENSION

SUN PHARMACEUTICAL INDUSTRIES: PHARMA COMPLETES 100% ACQUISITION OF ANTIBE THERAPEUTICS FOR CAD 4.5 MILLION

LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR AMIFAMPRIDINE TABLETS -- CO ESTIMATED GLOBAL NET SALES OF USD 306 MILLION

LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR AMIFAMPRIDINE TABLETS

LAURUS LABS: CO INVESTS RUPEES 83 CR IN KRKA PHARMA VIA RIGHTS ISSUE

ALKEM LABS: CO SAYS US FDA INSPECTION AT COS BIOEQUIVALENCE CENTER LOCATED AT TALOJA -- CO SAYS NO FORM 483 ISSUED AFTER FDA INSPECTION AT ALKEMS TALLOJA CENTER

ZYDUS LIFESCIENCES: ZYNEXT VENTURES INVESTS IN ILLEXCOR THERAPEUTICS -- INVESTMENT TO ADVANCE NOVEL ORAL THERAPY FOR SICKLE CELL DISEASE

ZYDUS LIFE: CO RECEIVES FINAL APPROVAL FROM USFDA FOR METHENAMINE HIPPURATE TABLETS USP, 1 GRAM

GLENMARK PHARMA: CO EXPANDS CARDIOMETABOLIC PORTFOLIO WITH THE LAUNCH OF EMPAGLIFLOZIN AND ITS FIXED-DRUG COMBINATIONS IN INDIA

ALKEM LABS: COLAUNCHES GENERIC EMPAGLIFLOZIN AND ITS COMBINATIONS IN INDIA UNDER THE BRAND NAME “EMPANORM”

ZYDUS LIFESCIENCES: CO PLANS TO DELIST AMPLITUDE SURGICAL AFTER ACQUISITION

ZYDUS LIFESCIENCES: CO TO ACQUIRE 85.6% STAKE IN AMPLITUDE SURGICAL

ZYDUS LIFESCIENCES: CO ACQUISITION PRICE EURO 6.25 PER SHARE, TOTAL VALUE EURO 256.8 MILLION

LAURUS LABS: US STATE SEC RUBIO: WERE OFFICIALLY CANCELLING 83% OF THE PROGRAMS AT USAID

DR REDDYS: DOMESTIC PHARMA FIRMS TO ROLL OUT LOW-COST EMPAGLIFLOZIN FOR DIABETES CARE - MC

LUPIN: CURRENTLY PRICED AT RS 60 PER TABLET, EMPAGLIFLOZIN’S GENERIC VERSIONS WILL BE AVAILABLE FOR AS LOW AS RUPEES 9-RUPEES 14 PER TABLET, SIGNIFICANTLY REDUCING COSTS FOR MILLIONS OF PATIENTS, STATES THE REPORT. - MC

LUPIN: DOMESTIC PHARMA FIRMS TO ROLL OUT LOW-COST EMPAGLIFLOZIN FOR DIABETES CARE - MC

TORRENT PHARMA: DOMESTIC PHARMA FIRMS TO ROLL OUT LOW-COST EMPAGLIFLOZIN FOR DIABETES CARE - MC

MANKIND PHARMA: CURRENTLY PRICED AT RS 60 PER TABLET, EMPAGLIFLOZIN’S GENERIC VERSIONS WILL BE AVAILABLE FOR AS LOW AS RUPEES 9-RS 14 PER TABLET, SIGNIFICANTLY REDUCING COSTS FOR MILLIONS OF PATIENTS, STATES THE REPORT. - MC

MANKIND PHARMA: DOMESTIC PHARMA FIRMS TO ROLL OUT LOW-COST EMPAGLIFLOZIN FOR DIABETES CARE - MC

ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM USFDA FOR KETOCONAZOLE SHAMPOO, 2% -- KETOCONAZOLE SHAMPOO HAD ANNUAL SALES OF USD 68.89M IN THE UNITED STATES (IQVIA MAT JANUARY 2025)

GRANULES INDIA: USFDA REBUKES CO FOR LAPSES IN MAINTAINING STORAGE FACILITIES, EQUIPMENT AT TELANGANA PLANT - BUSINESSLINE

GLENMARK PHARMA: GLENMARK THERAPEUTICS INC., USA LAUNCHES POLYETHYLENE GLYCOL 3350, POWDER FOR SOLUTION, 17 GRAMS/CAPFUL (OTC) -- THIS SOLUTIONS ACHIEVED ANNUAL SALES OF APPROXIMATELY USD 555M

SUN PHARMA: CO TO ACQUIRE CHECKPOINT THERAPEUTICS FOR UP TO USD 355M (30.97B RUPEES)

J.B. CHEMICALS: CO INFORMS THAT USFDA COMPLETES INSPECTION OF PANOLI FACILITY WITH ‘NO OBSERVATIONS’ AND NO FORM 483 WAS ISSUED

BIOCON: CO UNIT BIOCON BIOLOGICS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDY OF YESINTEK™ BIOSIMILAR TO USTEKINUMAB FOR CHRONIC PLAQUE PSORIASIS -- YESINTEK DEMONSTRATES EQUIVALENT EFFICACY AND SAFETY TO STELARA

LUPIN: CO LAUNCHES RIVAROXABAN TABLETS USP, 2.5MG IN THE UNITED STATES -- US SALES OF USD 446 MILLION

BIOCON: CO UNIT BIOCON BIOLOGICS AND CIVICA, INC. COLLABORATE TO EXPAND INSULIN ASPART ACCESS IN THE UNITED STATES

LAURUS LABS: CO APPROVES 833M RUPEES INVESTMENT IN KRKA PHARMA -- CO TO ACQUIRE 83.3M EQUITY SHARES IN KRKA PHARMA -- KRKA D.D. TO INVEST 867M RUPEES IN KRKA PHARMA

ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM USFDA FOR DASATINIB TABLETS -- US SALES OF 1.81B USD

Biocon Ltd.: Rs. 19.60 Crores NSE Block Trade; for ~ 603,674 Shares, at Rs. 324.75

AUROBINDO PHARMA: TERMINATION OF LICENSE AGREEMENT WITH HILLEMAN LABORATORIES SINGAPORE

ZYDUS LIFESCIENCES: THE INTRODUCTION OF ANVIMO MARKS A NEW ERA IN BONE MARROW TRANSPLANT AND KIDNEY TRANSPLANT CARE IN INDIA

ZYDUS LIFESCIENCES: CO LAUNCHES ANVIMO, A BREAKTHROUGH FOR TRANSPLANT PATIENTS

BIOCON: CO SUBSIDIARY RECEIVED FINAL APPROVALS FOR ITS ANDAS FROM U.S. FDA -- APPROVALS FOR LENALIDOMIDE CAPSULES, DASATINIB TABLETS -- BIOCON PHARM RECEIVED TENTATIVE APPROVAL FOR RIVAROXABAN TABLETS

GRANULES INDIA: IBUPROFEN PRICES SURGE AS SUPPLY CHAIN DISRUPTIONS AND TARIFFS DRIVE COSTS HIGHER

ZYDUS LIFESCIENCES: PROJECT SUPPORTED BY GATES FOUNDATION TO START IN MARCH 2025

ZYDUS LIFESCIENCES: CO SUPPORTED BY THE GATES FOUNDATION, TO DEVELOP THE WORLD’S FIRST COMBINATION VACCINE TO OFFER PROTECTION AGAINST SHIGELLOSIS AND TYPHOID FOR INFANTS AND CHILDREN

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA ACQUIRES AND LAUNCHES ACETYLCYSTEINE INJECTION, 6 GM/30 ML (200 MG/ML) SINGLE-DOSE VIALS -- ACCORDING TO IQVIA SALES DATA FOR THE 12-MONTH PERIOD ENDING JANUARY 2025, THE ACETADOTE® INJECTION, 6 GM/30 ML (200 MG/ML) SINGLE-DOSE VIALS MARKET ACHIEVED ANNUAL SALES OF APPROXIMATELY $15.2M

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA ACQUIRES AND LAUNCHES ACETYLCYSTEINE INJECTION,SINGLE-DOSE VIALS -- THIS INJECTION ACHIEVED ANNUAL SALES OF APPROX. USD 15.2M

MANKIND PHARMA: CO SAYS INCOME TAX DEPARTMENT RAISES ADDITIONAL TAX DEMAND OF 1.12B RUPEES; BELIEVES TAX DEMAND IS NOT TENABLE IN LAW -- CO SAYS DOES NOT EXPECT MATERIAL IMPACT ON FINANCIALS OR OPERATIONS; TO PURSUE APPEAL AGAINST INCOME TAX ORDER

AUROBINDO PHARMA: CO HAS ANNOUNCED THE SUCCESSFUL COMPLETION OF ITS ACQUISITION OF 80% OF THE EQUITY SHARE CAPITAL OF TERGENE BIOTECH, A STEP-DOWN SUBSIDIARY AND JOINT VENTURE COMPANY

MANKIND PHARMA: TODAY 3PM MSCI INDIA STANDARD INDEX WEIGHTAGE UP INFLOW $48 MILLION (RS 4.19B)

TORRENT PHARMA: TODAY 3PM MSCI INDIA STANDARD INDEX WEIGHTAGE UP INFLOW $43 MILLION (RS 3.76B)

BIOCON LIMITED: CO LAUNCHES ITS GLUCAGON-LIKE PEPTIDE-1 (GLP -1), LIRAGLUTIDE, IN THE UNITED KINGDOM

DR. REDDYS LABS: CO SECURES FDA TENTATIVE APPROVAL FOR NILOTINIB ANDA

MANKIND PHARMA: NCLT APPROVES AMALGAMATION OF SHREE JEE LAB, JPR LABS, JASPACK WITH CO

GRANULES INDIA: USFDA ISSUES WARNING LETTER TO GRANULES GAGILLAPUR FACILITY; USFDA HAS NOT INDICATED FURTHER ESCALATION -- WARNING LETTER MAY IMPACT FDA REVIEW OF PENDING SUBMISSIONS; MANUFACTURING OF EXISTING PRODUCTS FROM GAGILLAPUR FACILITY CONTINUE UNAFFECTED

DR REDDY: CO SUBSIDIARY AURIGENE PHARMA SAYS ASPIRE TO BE ABOVE INDUSTRY GROWTH RATE OF 15% - CNBC TV18

DR REDDY: CO SAYS GROWTH OPPORTUNITY FOR THE INDIA CDMO BUSINESS IS HUGE - CNBC TV18

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA LAUNCHES EPINEPHRINE INJECTION USP, 10 MG/10 ML, MULTIPLE-DOSE VIAL -- THIS INJECTION HAS ACHIEVED ANNUAL SALES OF APPROXIMATELY USD 42.7M

ZYDUS LIFESCIENCES: CO FIRST IN INDIA TO LAUNCH PROTECTION AGAINST NEW STRAIN OF INFLUENZA VIRUS (SOUTHERN HEMISPHERE 2025) -- CO SAYS QUADRIVALENT VACCINE CLEARED BY CENTRAL DRUG LABORATORY

DR REDDYS LABORATORIES: CO UPDATES ON USFDA INSPECTION AT API MANUFACTURING FACILITY (CTO-2) IN BOLLARAM -- CO HAS RECEIVED THE ESTABLISHMENT INSPECTION REPORT (EIR); USFDA HAS CLASSIFIED THE INSPECTION AS VOLUNTARY ACTION INDICATED (VAI) AND CONCLUDED THAT THE INSPECTION IS "CLOSED"

DR. REDDYS LABORATORIES LTD.: RS. 191.06 CRORES NSE BLOCK TRADE; FOR ~ 1,691,227 SHARES, AT RS. 1129.70

GLAND PHARMA: INSPECTION WAS CONCLUDED WITH THREE OBSERVATION

GLAND PHARMA: CO CONCLUSION OF US FDA INSPECTION AT JNPC FACILITY

BIOCON: BIOCON BIOLOGICS LAUNCHES YESINTEK™ (USTEKINUMAB-KFCE) BIOSIMILAR TO STELARA® IN THE UNITED STATES -- YESINTEK WILL BE AVAILABLE IN ALL THE SAME FORMULATIONS CURRENTLY PROVIDED BY STELARA; AVAILABLE PRESENTATIONS ARE 45 MG/0.5 ML PFS, 90 MG/ML PFS, 45 MG/0.5 ML VIAL, AND 130 MG/26 ML VIAL

GLENMARK PHARMA: CO TO ENTER SETTLEMENT WITH HUMANA, CENTENE, KAISER -- HUMANA, CENTENE, KAISER SETTLEMENT FOR USD 7M

LUPIN: THE GENERIC DRUG INDUSTRY IS EXPERIENCING A MOVEMENT TOWARD CENTRALIZING PRODUCTION IN INDIA AND CHINA DUE TO THEIR SIGNIFICANTLY LOWER COSTS AND LOOSER MANUFACTURING STANDARDS

ZYDUS LIFESCIENCES: THE GENERIC DRUG INDUSTRY IS EXPERIENCING A MOVEMENT TOWARD CENTRALIZING PRODUCTION IN INDIA AND CHINA DUE TO THEIR SIGNIFICANTLY LOWER COSTS AND LOOSER MANUFACTURING STANDARDS

AUROBINDO: THE GENERIC DRUG INDUSTRY IS EXPERIENCING A MOVEMENT TOWARD CENTRALIZING PRODUCTION IN INDIA AND CHINA DUE TO THEIR SIGNIFICANTLY LOWER COSTS AND LOOSER MANUFACTURING STANDARDS

LUPIN: CONGRESSWOMAN TENNEY REINTRODUCES PILLS ACT TO PROMOTE PRODUCTION OF GENERIC MEDICINE IN THE U.S.

AUROBINDO: CONGRESSWOMAN TENNEY REINTRODUCES PILLS ACT TO PROMOTE PRODUCTION OF GENERIC MEDICINE IN THE U.S.

GRANULES INDIA: CO TO ACQUIRE 100% EQUITY STAKE IN SENN CHEMICALS AG -- DEAL FOR 1.93 BLN RUPEES

LUPIN: CO RECEIVES EIR FROM U.S. FDA FOR ITS SOMERSET MANUFACTURING FACILITY, FOR THE INSPECTION CONDUCTED FROM JANUARY 27 TO JANUARY 31, 2025

LAURUS LABS: DESPITE COURT RULING FUNDS NOT RELEASED FOR USAID HIV - NEWYORK TIMES

DIVIS LABORATORIES LTD.: RS. 118.07 CRORES NSE BLOCK TRADE; FOR ~ 203,922 SHARES, AT RS. 5790.00

DR. REDDYS LABORATORIES LTD.: RS. 175.02 CRORES NSE BLOCK TRADE; FOR ~ 1,507,932 SHARES, AT RS. 1160.65

CIPLA: CO UPDATES USFDA HAS CONDUCTED CGMP INSPECTION AT THE ANALYTICAL TESTING FACILITY OF SITEC LABS LIMITED, NAVI MUMBAI FROM 18TH TO 20TH FEB, SITEC RECEIVED 2 OBSERVATIONS IN FORM 483

CIPLA: CO GETS FINAL APPROVAL FROM US FDA FOR NEW DRUG APPLICATION (NDA) SUBMITTED FOR NILOTINIB CAPSULES 50, 150 & 200 MG -- NILOTINIB IS USED FOR TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML) -- PRODUCT IS EXPECTED TO BE LAUNCHED IN FY2025-26 IN USA

ZYDUS LIFESCIENCES: AMNEAL LAUNCHES MESALAMINE AND RECEIVES U.S. FDA APPROVAL FOR LENALIDOMIDE -- COMPETITION LAUNCHES G ASACOL, GETS APPROVAL FOR GREVLIMID - BUSINESSWIRE

AUROBINDO PHARMA: CO UPDATES THE INSPECTION HAD CONCLUDED WITH 5 OBSERVATIONS

AUROBINDO PHARMA: CO UPDATES THAT US FDA CLASSIFIES NEW JERSEY WAREHOUSE INSPECTION AS OAI

AUROBINDO PHARMA: CO SAYS COMPLETION OF US FDA PRE-APPROVAL INSPECTION AT EUGIA STERILES -- INSPECTION CONCLUDES WITH 5 PROCEDURAL OBSERVATIONS

BIOCON: EUROPEAN COMMISSION APPROVES BIOCON BIOLOGICS’ USTEKINUMAB BIOSIMILAR

GLENMARK PHARMA: U.S. FDA INSPECTION AT THE COS FACILITY AT INDORE; CO WAS ISSUED A FORM 483 WITH FIVE OBSERVATIONS -- NO OBSERVATION RELATED TO DATA INTEGRITY REPORTED; CO SAYS WILL WORK TO ADDRESS OBSERVATIONS

GLENMARK PHARMA: CO SAYS EXPECT NORTH AMERICA BUSINESS TO GAIN MOMENTUM FROM FY26 ONWARDS

GLENMARK PHARMA: Q3 EBITDA GAIN 6B RUPEES VS LOSS 2.1B(YOY) -- Q3 EBITDA MARGIN 18.18%

GLENMARK PHARMA: Q3 CONS NET PROFIT 3.5B RUPEES VS LOSS 4.7B (YOY) -- Q3 REVENUE 33B RUPEES VS 24.6B (YOY)

ZYDUS LIFESCIENCES: CO SAYS USFDA CONDUCTED A SURVEILLANCE INSPECTION AT THE GROUP’S API MANUFACTURING SITE SITUATED AT AMBERNATH IN MAHARASHTRA -- CO SAYS INSPECTION CONCLUDED WITH NIL OBSERVATIONS

ZYDUS: CO AND BEIHAI BIOTECH SIGN AN LICENSING, SUPPLY AND COMMERCIALIZATION AGREEMENT FOR BEIZRAY A 505(B)(2) PRODUCT FOR THE US MARKET

ZYDUS LIFE: CO UPDATED STOCK EXCHANGE ON CLOSURE OF USFDA INSPECTION AT ZYDUS TOPICAL PLANT WITH NIL OBSERVATIONS

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA LAUNCHES LATANOPROST OPHTHALMIC SOLUTION -- THIS SOLUTION ACHIEVED ANNUAL SALES OF APPROXIMATELY USD 113M

IPCA LABS: CO IS DEVELOPING PRODUCTS FOR COSMETO DERMATOLOGY, WITH A LINEUP OF PRODUCTS IN THE PIPELINE -- CO HAS STARTED A NEW DIVISION CALLED FLEXICARE, WHICH WILL ADD PRODUCTS USED BY ORTHOPEDICS - CONCALL UPDATE

GLENMARK PHARMA: USA LAUNCHES LATANOPROST OPHTHALMIC SOLUTION, 0.005% (0.05 MG/ML)

IPCA LABS: CO ANTICIPATES 100 BASIS POINTS TO 150 BASIS POINT MARGIN IMPROVEMENT OVER THE NEXT THREE TO FOUR YEARS -- OVERALL GUIDANCE FOR THE YEAR WAS AROUND 21%, BUT CO EXPECTS STANDALONE EBITDA TO REMAIN IN THE RANGE OF 23% TO 24% FOR THE WHOLE FINANCIAL YEAR - CONCALL UPDATE

IPCA LABS: COS OVERALL GUIDANCE FOR THE YEAR IS AN EBITDA MARGIN OF AROUND 21% -- CO EXPECTS ITS EBITDA MARGIN FOR THE WHOLE FINANCIAL YEAR TO REMAIN IN THE RANGE OF 23% TO 24% - CONCALL UPDATE

AUROBINDO PHARMA: CO SAYS EUROPEAN COMMISSION (EC) GRANTED MARKETING AUTHORIZATION IN THE EUROPEAN UNION (EU) FOR ZEFYLTI®, A FILGRASTIM BIOSIMILAR, TO UNIT CURATEQ BIOLOGICS S.R.O.

IPCA LABORATORIES: Q3 REVENUE 22.4B RUPEES VS 20.5B (YOY)

IPCA LABORATORIES: Q3 EBITDA 4.63B RUPEES VS 3.31B (YOY);EST: 4.20B -- Q3 EBITDA MARGIN 20.62% VS 16.14% (YOY);EST: 18%

IPCA LABORATORIES: Q3 CONS NET PROFIT 2.5B RUPEES VS 1.8B (YOY); EST 2.11B

DR. REDDYS LABORATORIES LTD.: RS. 297.34 CRORES NSE BLOCK TRADE; FOR ~ 2,425,449 SHARES, AT RS. 1225.90

LUPIN: CO HAS A STRONG PIPELINE WITH OVER 20 RESPIRATORY PRODUCTS AND 40 INJECTABLE PRODUCTS IN DEVELOPMENT -- CO PLANS TO FILE MORE THAN 30 ANDAS IN THE NEXT TWO YEARS, WITH OVER 50% BEING COMPLEX PRODUCTS - CONCALL UPDATE

LUPIN: CO SAYS ON A QUARTER-ON-QUARTER BASIS, EBITDA MARGINS HAVE EXPANDED BY 51 BASIS POINTS. THE COMPANY AIMS FOR AN OVERALL MARGIN RANGE OF 22.5% TO 23.5% FOR THE NEXT FISCAL YEAR - CONCALL UPDATE

LUPIN: CO EXPECTS A STRONGER TAIL FOR A SPECIALTY PRODUCT, WHICH SHOULD BE MEANINGFUL IN THE SECOND HALF OF THE FISCAL YEAR AND INTO FISCAL YEAR 27 -- COS MARGINS ARE THE HIGHEST THEY HAVE ACHIEVED IN THE LAST FIVE YEARS, DESPITE HIGHER INVESTMENTS IN R&D DURING THE PERIOD - CONCALL UPDATE

LUPIN: CO BELIEVES IT SHOULD BE ABLE TO DELIVER EBITDA MARGINS IN THE REGION OF 23% AND 23.5% RANGE IN FY25 -- CO EXPECTS THE EFFECTIVE TAX RATE (ETR) TO BE ABOUT 20% TO 21% FOR THE FULL YEAR - CONCALL UPDATE

LUPIN: CO EXPECTS R&D SPEND TO BE AROUND RS 1,800 CR FOR FISCAL YEAR 25, WITH A SIGNIFICANT INCREASE IN QUARTER FOUR -- CO ANTICIPATES ITS US BUSINESS TO DELIVER DOUBLE-DIGIT GROWTH IN FY25, AHEAD OF ITS EARLIER GUIDANCE OF HIGH SINGLE-DIGIT GROWTH IN THE SEGMENT - CONCALL UPDATE

ZYDUS LIFESCIENCES: ZYDUS AND SYNTHON SIGN AN EXCLUSIVE DEVELOPMENT, LICENSING, SUPPLY AND COMMERCIALIZATION AGREEMENT FOR A NOVEL 505(B)(2) ONCOLOGY PRODUCT FOR THE US MARKET -- ADDRESSABLE MARKET SIZE OF REFERENCE PRODUCT IS APPROXIMATELY US$1.5 BILLION AS PER IQVIA MAT DEC 2024

NATCO PHARMA: Q3 EBITDA 388M RUPEES VS 2.68B (YOY) -- Q3 EBITDA MARGIN 8.17% VS 35.34% (YOY)

NATCO PHARMA: Q3 CONS NET PROFIT 1.33B RUPEES VS 2.13B (YOY) -- Q3 REVENUE 4.75B RUPEES VS 7.6B (YOY)

GLAND PHARMA: THREE GLOBAL PE FIRM TO BUY COS STAKE FROM CHINESE OWNER - MINT

LAURUS LABS: U.S.- WE HAVE TURNED ON FUNDING FOR EBOLA AND HIV PREVENTION.

GLENMARK PHARMA: GLENMARK PHARMA INC., USA LAUNCHES CLINDAMYCIN PHOSPHATE FOAM, 1%

LUPIN: CO UPDATES REGARDING INCORPORATION OF UNIT IN THE NAME AND STYLE “LUPINLIFE CONSUMER HEALTHCARE LTD” OR ANY OTHER APPROPRIATE NAME, AS MAY BE APPROVED BY THE MINISTRY OF CORPORATE AFFAIRS

LUPIN: CO TO HIVE OFF OTC CONSUMER HEALTHCARE BUSINESS INTO UNT VIA SLUMP SALE FOR RUPEES 550 - 650 CR

LUPIN: NORTH AMERICA Q3 FY2025 SALES WERE RUPEES 21B , UP 12.3% COMPARED TO RUPEES 18.8B IN Q3 FY2024; ACCOUNTING FOR 38% OF LUPIN’S GLOBAL SALES

LUPIN: Q3 EBITDA 13.56B RUPEES VS 10.3B (YOY) -- Q3 EBITDA MARGIN 23.5% VS 19.9% (YOY)

LUPIN: Q3 CONS NET PROFIT 8.55B RUPEES VS 6.13B (YOY) -- Q3 REVENUE 57.7B RUPEES VS 51.9B (YOY)

MANKIND PHARMA: CO SELLS STAKE IN MAHANANDA SPA TO CHALET HOTELS -- TRANSACTION VALUED AT 5.3B RUPEES

LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR IPRATROPIUM BROMIDE NASAL SOLUTION (NASAL SPRAY), 0.03% -- IPRATROPIUM BROMIDE NASAL SOLUTION (NASAL SPRAY), 0.03% (RLD ATROVENT®) HAD ESTIMATED ANNUAL SALES OF USD 22M IN THE U.S. (IQVIA MAT DECEMBER 2024)

GLENMARK PHARMA: COSMO AND CO ANNOUNCE UK MHRA APPROVAL OF WINLEVI® FOR TREATMENT OF ACNE

NATCO PHARMA: CO AND ITS ALLIANCE PARTNER LUPIN ANNOUNCES APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION (ANDA) FOR BOSENTAN TABLETS FOR ORAL SUSPENSION

ALKEM LABS: CO EXPECTS TO CLOSE AT AROUND RS. 300 CR FOR FY25, WITH A GROWTH RATE OF 15% TO 20% IN THE NEXT YEAR FROM THE PUNE UNIT -- CO IS SEEING GROWTH IN EBITDA MARGINS -- CO PLANS TO LAUNCH TOPIRAMATE ORAL SOLUTION IN THE COMING YEAR - CONCALL UPDATE

ALKEM LABS: CO IS ON TRACK TO MEET ITS EARLIER GUIDANCE FOR OVERALL MARGIN, WITH AN ESTIMATE OF AROUND 19% FOR Q4 -- GUIDANCE FOR NON-US MARKETS IS 13% TO 14% GROWTH - CONCALL UPDATE

ALKEM LAB: Q3FY25 INTERNATIONAL SALES WERE ₹ 9,60M, WITH YOY DE-GROWTH OF 6.2% -- OVERALL CONTRIBUTION OF US SALES TO TOTAL SALES WAS 19.1% IN Q3FY25

ALKEM LABORATORIES: Q3 REVENUE 34B RUPEES VS 33B (YOY)

ALKEM LABORATORIES: Q3 EBITDA 7.6B RUPEES VS 7.08B (YOY); EST 7.12B -- Q3 EBITDA MARGIN 22.51% VS 21.29% (YOY); EST 20.5%

ALKEM LABORATORIES: CO DECLARED DIVIDEND OF 37 RUPEES

ALKEM LABORATORIES: Q3 CONS NET PROFIT 6.3B RUPEES VS 5.9B (YOY); EST 6.15B

AUROBINDO PHARMA: COS WITH VERY STRONG GUIDANCE OF BIOSIMILARS -- US AT USD 435M (UP 3% QOQ) THE HIGHEST IN THE LAST 4 QS, ESP ALTER EUGLA PLANT WAS HIT BY A FORM 433 / 8. THEN OAL -- THIS IS IKELY DUE LO STRONG BASE BUSINESS IMPROVEMENT, SHOULD ALLAY CONCERNS AROUND PRICE EROSION

AUROBINDO PHARMA: CO APPROVES MAKING TERGENE BIOTECH LTD A DIRECT UNIT

AUROBINDO PHARMA: Q3 EBITDA 15.78B RUPEES VS 16.83B (YOY); EST 16.35B -- Q3 EBITDA MARGIN 19.99% VS 23.15% (YOY); EST 21%

AUROBINDO PHARMA: Q3 CONS NET PROFIT 8.46B RUPEES VS 9.4B (YOY); EST 9.05B -- Q3 REVENUE 78.9B RUPEES VS 72.71B (YOY); EST 77.8B

BIOCON: EQUILLIUM INC. AND CO ANNOUNCE POSITIVE DATA FROM PHASE 2 STUDY EVALUATING ITOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

DR REDDYS LABORATORIES: CO UNIT ENTERS LICENSE AGREEMENT WITH HENLIUS BIOTECH FOR DARATUMUMAB -- DEAL VALUED AT $131.6M WITH $33M UPFRONT PAYMENT

ZYDUS LIFE: CO HAS A ROBUST LAUNCH PIPELINE IN INDIA, INCLUDING DAY ONE LAUNCHES OF PATENT MOLECULES, COMPLEX GENERICS, AND BIOLOGICS -- CO HAS A PIPELINE OF UPCOMING LAUNCHES IN THE NEXT THREE TO FOUR YEARS - CONCALL UPDATE

ZYDUS LIFE: CO BELIEVES IT CAN ACHIEVE +23% EBITDA MARGIN IN THE NEXT ONE OR TWO YEARS. THE EXPANSION INTO NEW MARKETS, SUCH AS THE MIDDLE EAST AND SAUDI, HAS CONTRIBUTED TO A BETTER MARGIN PROFILE - CONCALL UPDATE

ZYDUS LIFE: CO EXPECTS HIGH SINGLE-DIGIT GROWTH IN THE U.S. OVERALL GEOGRAPHY FOR FY 26, ASSUMING CERTAIN SCENARIOS PAN OUT -- CO EXPECTS TO BREAK EVEN AND TURN PROFITABLE IN FY 26 FOR THE SENTYNL THERAPEUTICS BUSINESS - CONCALL UPDATE

ZYDUS LIFESCIENCES: CO US FORMULATION SALES USD 285M Q3 FY25 YOY GROWTH OF 30.8%

ZYDUS LIFESCIENCES: Q3 REVENUE 52.7B RUPEES VS 45B (YOY); EST 52.87B

ZYDUS LIFESCIENCES: Q3 EBITDA 14B RUPEES VS 11.02B (YOY); EST 14.15B -- Q3 EBITDA MARGIN 26.3% VS 24.47% (YOY); EST 26.7%

ZYDUS LIFESCIENCES: Q3 CONS NET PROFIT 10.2B RUPEES VS 7.9B (YOY); EST 9.2B

SUN PHARMA: CO GETS TAX PENALTY OF 1.60B RUPEES

J.B.CHEMICALS & PHARMACEUTICALS: Q3 EBITDA 2.55B RUPEES VS 2.23B (YOY) -- Q3 EBITDA MARGIN 26.42% VS 26.42% (YOY)

J.B.CHEMICALS & PHARMACEUTICALS: Q3 CONS NET PROFIT 1.62B RUPEES VS 1.34B (YOY) -- Q3 REVENUE 9.6B RUPEES VS 8.44B (YOY)

LUPIN: CO HAS RECEIVED TENTATIVE APPROVAL FROM THE U.S. FDA FOR ITS ABBREVIATED NEW DRUG APPLICATION FOR DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE TABLETS, 800 MG/150 MG/200 MG/10 MG -- CO HAS CLARIFIED THAT THIS APPROVAL IS NOT CONSIDERED MATERIAL UNDER THE SEBI LISTING REGULATIONS, AND THEREFORE, WAS NOT DISCLOSED TO THE STOCK EXCHANGES

ALKEM LAB: CO LAUNCHES KOJIGLO SERUM IN INDIA TO MANAGE FACIAL HYPERPIGMENTATION

SUN PHARMA: PHILOGEN COMPLETES PATIENT ENROLLMENT OF THE PHASE III FIBROSARC TRIAL IN SOFT TISSUE SARCOMA

DIVIS LABS: CO IS WORKING WITH INNOVATORS ON DEVELOPING NEW GADOLINIUM COMPOUNDS, WHICH ARE AT DIFFERENT STAGES OF DEVELOPMENT - CONCALL UPDATE

DIVIS LABS: COS ADDITIONS TO ITS GENERIC PORTFOLIO ARE EXPECTED TO PLAY A CRUCIAL ROLE IN DRIVING FUTURE GROWTH, PARTICULARLY AS THE CO APPROACHES A WAVE OF PATENT EXPIRATIONS - CONCALL UPDATE

DIVIS LABS: CO TARGETS A DOUBLE-DIGIT GROWTH YEAR-OVER-YEAR, WITH A FOCUS ON STABLE DOUBLE-DIGIT GROWTH -- CO EXPECTS TO SEE RESULTS FROM THE COMPLETION OF KAKINADA PHASE 1 IN THE COMING SIX MONTHS, WHICH WILL IMPACT NUTRACEUTICAL VOLUMES AND PRODUCTION CAPACITY - CONCALL UPDATE

GLAND PHARMA: CO SAYS CENEXIS NEW HIGH-CAPACITY AMPOULE LINE BEGAN PRODUCTION ON SCHEDULE -- THIS ADDITION WILL INCREASE AMPOULE MANUFACTURING CAPACITY BY 40–50 MILLION UNITS, ALLOWING FOR BETTER SERVICE TO CUSTOMERS MOVING FORWARD - INVESTOR PRESENTATION

GLAND PHARMA: CO SAYS CENEXI MAINTAINS ITS GOAL OF ACHIEVING A POSITIVE EBITDA FOR THE NEXT FISCAL YEAR, DRIVEN BY AN INCREASE IN REVENUE ABOVE THE €200 MILLION THRESHOLD - INVESTOR PRESENTATION

GLAND PHARMA: Q3 EBITDA 3.6B RUPEES VS 3.56B (YOY) -- Q3 EBITDA MARGIN 26% VS 23.07% (YOY)

GLAND PHARMA: Q3 CONS NET PROFIT 2.05B RUPEES VS 1.92B (YOY); 1.6B (QOQ) -- Q3 REVENUE 13.84B RUPEES VS 15.4B (YOY)

CIPLA: CO TO INVEST ZAR 900 MILLION IN SOUTH AFRICAN SUBSIDIARY

DIVIS LAB: CO HAS CONTINUED TO DELIVER STEADY GROWTH IN BOTH REVENUE AND OPERATIONS, DRIVEN BY OUR FOCUSED EFFORTS TO CAPITALIZE ON EMERGING OPPORTUNITIES IN THE GENERIC AND CDMO SEGMENTS - CONCALL UPDATE

DIVIS LABORATORIES: Q3 EBITDA 7.43B RUPEES VS 5B (YOY); EST 6.99B -- Q3 EBITDA MARGIN 32.04% VS 26.90% (YOY); EST 31%

DIVIS LABORATORIES: Q3 CONS NET PROFIT 5.89B RUPEES VS 3.58B (YOY); EST 5.07B -- Q3 REVENUE 23B RUPEES VS 18.6B (YOY); EST 22.87B

LUPIN: CO ANNOUNCES CLOSURE OF INSPECTION BY U.S. FDA AT ITS SOMERSET FACILITY WITH NO OBSERVATIONS

AUROBINDO PHARMA: CO SAYS CURATEQ BIOLOGICS RECEIVES POSITIVE OPINION FOR BIOSIMILAR DYRUPEG FROM EMA -- EXPECTED TO GET APPROVAL FOR DYRUPEG BY EUROPEAN COMMISSION IN APRIL 2025

SUN PHARMA: US FORMULATION SALES AT USD 474M, DOWN 0.7% VS EST USD 511M

SUN PHARMACEUTICAL INDUSTRIES: Q3 EBITDA 40.08B RUPEES VS 34.8B (YOY); EST 37B -- Q3 EBITDA MARGIN 29.3% VS 28.08% (YOY); EST 28%

SUN PHARMACEUTICAL INDUSTRIES: Q3 REVENUE 136.7B RUPEES VS 124B (YOY); EST 132B

SUN PHARMACEUTICAL INDUSTRIES: Q3 CONS NET PROFIT 29B RUPEES VS 25.2B (YOY); EST 28.8B

BIOCON: CO EXPECT PERFORMANCE IN Q4FY25 AND BEYOND TO BUILD UPON SEQUENTIAL REVENUE GROWTH IN Q3. GROWTH TO BE DRIVEN BY NEW PRODUCT LAUNCHES ACROSS MARKETS - INVESTOR PRESENTATION

BIOCON: CO BOARD APPROVES PURCHASE OF EQUITY SHARES OF BIOCON BIOLOGICS; EQUITY SHAREHOLDING IN BBL TO INCREASE BY 1.5% -- COST OF ACQUISITION IS 5,550M RUPEES

BIOCON: CO SAYS BIOSIMILARS BUSINESS HAS CLEAR LINE OF SIGHT FOR NEW LAUNCHES BEGINNING IN Q4 -- CO SAYS RECOVERY IN GENERICS BUSINESS IN Q4 WILL BE DRIVEN BY LAUNCH OF FIRST GLP-1 GENERIC IN UK, EU

BIOCON: Q3 EBITDA 7.5B RUPEES VS 9.27B (YOY) -- Q3 EBITDA MARGIN 19.67% VS 23.44% (YOY)

BIOCON: Q3 CONS NET PROFIT 251M RUPEES VS 6.6B (YOY); LOSS 160M (QOQ) -- Q3 REVENUE 38.2B RUPEES VS 39.54B (YOY)

AJANTA PHARMA: Q3 EBITDA 3.21B RUPEES VS 3.14B (YOY) -- Q3 EBITDA MARGIN 27.99% VS 28.42% (YOY)

AJANTA PHARMA: Q3 REVENUE 11.46B RUPEES VS 11.05B (YOY)

AJANTA PHARMA: Q3 CONS NET 2.33B PROFIT RUPEES VS 2B (YOY); 2.16B (YOY)

GRANULES: CO STRENGTHENS ADHD PORTFOLIO WITH FDA APPROVAL FOR LISDEXAMFETAMINE DIMESYLATE CAPSULES

AUROBINDO: PEPFAR IS USD 7.5B RUPEES PROGRAM OVERSEEN BY THE STATE DEPARTMENT -RESUMES

AUROBINDO: THE TRUMP ADMINISTRATION ON TUESDAY ISSUED A WAIVER FOR LIFESAVING MEDICINES AND MEDICAL SERVICES, OFFERING A REPRIEVE FOR A WORLDWIDE H.I.V. TREATMENT PROGRAM THAT WAS HALTED LAST WEEK

LAURUS LABS: PEPFAR IS USD 7.5B RUPEES PROGRAM OVERSEEN BY THE STATE DEPARTMENT -RESUMES

CIPLA: PEPFAR IS USD 7.5B RUPEES PROGRAM OVERSEEN BY THE STATE DEPARTMENT -RESUMES

LAURUS LABS: THE TRUMP ADMINISTRATION ON TUESDAY ISSUED A WAIVER FOR LIFESAVING MEDICINES AND MEDICAL SERVICES, OFFERING A REPRIEVE FOR A WORLDWIDE H.I.V. TREATMENT PROGRAM THAT WAS HALTED LAST WEEK

CIPLA: THE TRUMP ADMINISTRATION ON TUESDAY ISSUED A WAIVER FOR LIFESAVING MEDICINES AND MEDICAL SERVICES, OFFERING A REPRIEVE FOR A WORLDWIDE H.I.V. TREATMENT PROGRAM THAT WAS HALTED LAST WEEK

AUROBINDO: US TO CONTINUE TO FUND HIV TREATMENT

NATCO PHARMA: CO ANNOUNCES APPROVAL OF ITS ANDA FOR EVEROLIMUS TABLETS FOR ORAL SUSPENSION (GENERIC OF AFINITOR DISPERZ®)

CIPLA: US TO CONTINUE TO FUND HIV TREATMENT

BIOCON: CO SAYS ISSUE OF COMMERCIAL PAPERS OF 5.7 BLN RUPEES

GRANULES INDIA: CO UNIT V RECEIVES EU GMP CERTIFICATE -- EU AUTHORITY CONDUCTED AUDIT OF GRANULES INDIA UNIT V IN NOVEMBER 2024

CIPLA: CURRENT LEVELS OF MARGIN ARE NOT SUSTAINABLE - CNBC TV18

CIPLA: 9MFY25 MARGIN AT 27% VS COS FY25 GUIDANCE OF 25%

CIPLA: Q3 REVENUE 70.73B RUPEES VS 65B (YOY); EST 68.7B

CIPLA: Q3 EBITDA 19.9B RUPEES VS 17.5B (YOY); EST 17.28B -- Q3 EBITDA MARGIN 28.12% VS 26.45% (YOY); EST 25%

CIPLA: Q3 CONS NET PROFIT 15.7B RUPEES VS 10.6B (YOY); EST 11.75B

AUROBINDO PHARMA: CO UNIT 2 OF APITORIA PHARMA RECEIVED EIR FROM US FDA WITH VAI CLASSIFICATION

LUPIN: CO TO CONSIDER Q3 RESULT ON FEB.11

LAURUS LABS: CO CLARIFES ON THE NEWS ITEM THAT CO REASONABLY BELIEVES THERE WILL NOT BE SIGNIFICANT IMPACT ON THE BUSINESS

LAURUS LABS: CO REASONABLY BELIEVES THERE WILL NOT BE SIGNIFICANT IMPACT ON THE BUSINESS

LAURUS LABS: FUNDING FOR AIDS RELIEF PROGRAM TO STOP AFTER FOREIGN AID PAUSE ORDERED

BIOCON: CO APPROVED ISSUANCE OF COMMERCIAL PAPERS OF RUPEES 570 CR ON PRIVATE PLACEMENT BASIS

TORRENT PHARMACEUTICALS: CO DECLARED INTERIM DIVIDEND RS 26 PER SHARE

TORRENT PHARMACEUTICALS: Q3 EBITDA 9.14B RUPEES VS 8.7B (YOY) -- Q3 EBITDA MARGIN 32.54% VS 31.81% (YOY)

TORRENT PHARMACEUTICALS: Q3 CONS NET PROFIT 5.03B RUPEES VS 4.4B (YOY) -- Q3 REVENUE 28.09B RUPEES VS 27.3B (YOY)

JB CHEMICALS & PHARMA: CO TO CONSIDER Q3 RESULT ON FEB.4

LAURUS LAB: CO COMMITTED TO 2025 HEALTHY GROWTH OUTLOOK, SUPPORTED BY SCHEDULED PROJECT DELIVERIES IN Q4

LAURUS LABS: CO CEO SAYS WITNESSED ROBUST GROWTH IN THE CDMO AND FDF DIVISION, PARTIALLY OFFSET BY SOFT API PERFORMANCE. HEALTHY COMMERCIAL EXECUTION IS OUR TOP PRIORITY AND OUR PERFORMANCE IS WELL ON TRACK WITH REVENUES ACCELERATING IN Q4

LAURUS LAB: CO FY 2025 OUTLOOK RETAINED; REVENUE GROWTH AND EBITDA MARGINS IMPROVEMENT, LED BY EXECUTION ON FEW LATE-PHASE CLINICAL PROJECTS ALONG WITH REDUCTION IN NET DEBT LEVERAGE

LAURUS LABS: Q3 REVENUE 14.1B RUPEES VS 12B (YOY)

LAURUS LABS: Q3 EBITDA 2.86B RUPEES VS 1.8B (YOY) -- Q3 EBITDA MARGIN 20.21% VS 15.18% (YOY)

LAURUS LABS: Q3 CONS NET PROFIT 930M RUPEES VS 231M (YOY)

GRANULES INDIA: CO MD SAYS CO IS ENHANCING QUALITY AND COMPLIANCE THROUGH SYSTEMIC IMPROVEMENTS ACROSS OUR OPERATIONS, INCLUDING GAGILLAPUR.

GRANULES INDIA: CO VOLUNTARILY PAUSED THE PRODUCTION AT THE GAGILLAPUR PLANT IN SEP-24 FOR RISK ASSESSMENT ON ACCOUNT OF THE US FDA OBSERVATIONS

GRANULES INDIA: Q3 REVENUE 11.3B RUPEES VS 11.55B (YOY)

GRANULES INDIA: Q3 EBITDA 2.3B RUPEES VS 2.5B (YOY) -- Q3 EBITDA MARGIN 20.24% VS 22.00% (YOY)

GRANULES INDIA: Q3 CONS NET PROFIT 1.18B RUPEES VS 1.26B (YOY)

DR REDDYS LABS: CO IS INCREASINGLY FOCUSING ON DEVELOPING COMPLEX GENERIC PIPELINES, INCLUDING PROMISING GLP-1 ASSETS AND BIOSIMILARS - CONCALL UPDATE

DR REDDYS LABS: CO EXPECTS R&D SPEND TO BE IN THE RANGE OF 8.5% TO 9% OF SALES FOR THE FULL FISCAL YEAR -- CO EXPECTS A NORMALIZED EFFECTIVE TAX RATE (ETR) OF AROUND 25% - CONCALL UPDATE

MANKIND PHARMA: Q3 EBITDA 8.30B RUPEES VS 6.06B (YOY) -- Q3 EBITDA MARGIN 25.7% VS 23.27% (YOY)

MANKIND PHARMA: Q3 CONS NET PROFIT 3.8B RUPEES VS 4.66B (YOY) -- Q3 REVENUE 32.30B RUPEES VS 26B (YOY)

CIPLA: CO SAYS RAJEEV KUMAR SINHA RESIGNS AS GLOBAL CHIEF MANUFACTURING OFFICE

DR. REDDYS LABORATORIES: Q3 EBITDA 22.7B RUPEES VS 20.23B (YOY); EST 23.4B -- Q3 EBITDA MARGIN 27.12% VS 27.96% (YOY); EST 28.1%

DR. REDDYS LABORATORIES: Q3 CONS NET PROFIT 14.14B RUPEES VS 13.8B (YOY); EST 15B -- Q3 REVENUE 83.8B RUPEES VS 72.37B (YOY); EST 83.5B

NATCO PHARMA: FDA ADDS BOXED WARNING ABOUT A RARE BUT SERIOUS ALLERGIC REACTION CALLED ANAPHYLAXIS WITH THE MULTIPLE SCLEROSIS MEDICINE GLATIRAMER ACETATE (COPAXONE, GLATOPA)

NATCO PHARMA: FDA NAMES COMPETITORS OF COS DRUGS IN RISK

BIOCON: CO TO CONSIDER RAISING OF FUNDS THROUGH ISSUANCE OF COMMERCIAL PAPERS OR ANY OTHER MODE ON PRIVATE PLACEMENT BASIS ON JAN 27

ZYDUS LIFESCIENCES: ZYDUS ANNOUNCES USFDA ORPHAN DRUG DESIGNATION TO USNOFLAST FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)

LAURUS LABS: CO SAYS US FDA ISSUED ONE OBSERVATION FOR FOREIGN SUBSIDIARY OF LAURUS LABS -- CO SAYS OBSERVATION ISSUED AFTER POST-MARKETING ADVERSE DRUG EXPERIENCE INSPECTION BY US FDA

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA LAUNCHES PHYTONADIONE INJECTABLE EMULSION USP, 10 MG/ML SINGLE DOSE AMPULES -- THIS INJECTION HAS ANNUAL SALES OF USD 19.7M

CIPLA: CO SAYS USFDA INSPECTION AT MANUFACTURING FACILITY OF MEDISPRAY IN KUNDAIM, GOA -- ON CONCLUSION OF INSPECTION, MEDISPRAY RECEIVED 1 (ONE) OBSERVATION IN FORM 483

GLAND PHARMA: CO RECEIVES ESTABLISHMENT INSPECTION REPORT (EIR) FROM THE US FDA

SUN PHARMACEUTICAL: CO TO ACQUIRE 100% STAKE IN ANTIBE THERAPEUTICS

GLAND PHARMA: CO SAYS SHYAMAKANT GIRI WILL ASSUME THE OFFICE OF CHIEF EXECUTIVE OFFICER

SUN PHARMA: ILUMETRI PEAK-SALES EXPECTATION INCREASED TO >€300M FROM ~€250M EARLIER

SUN PHARMA: GUIDANCE UPGRADE BY PARTNER ON ILUMYA - BIGGEST SPECIALTY DRUG OF CO -- ALMIRALL (MARKETING PARTER OF CO) HAS UPWARD REVISED GUIDANCE FOR KEY SUN PHARMA DRUG

LUPIN: CO LAUNCHES MINZOYA TM (LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS, USP AND FERROUS BISGLYCINATE TABLETS) IN THE UNITED STATES -- LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS, USP AND FERROUS BISGLYCINATE TABLETS (RLD BALCOLTRA®) HAD AN ESTIMATED ANNUAL SALE OF USD 24M IN THE U.S. (IQVIA MAT NOVEMBER 2024)

TORRENT PHARMACEUTICALS: CO TO CONSIDER Q3 AND INTERIM DIVIDEND ON JAN 24

LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR IVACAFTOR ORAL GRANULES - RTRS

LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR LOTEPREDNOL ETABONATE OPHTHALMIC GEL - RTRS

LUPIN: CO RECEIVES EIR FROM U.S. FDA FOR ITS PITHAMPUR UNIT-1 MANUFACTURING FACILITY THAT MANUFACTURES BOTH APIS AND FINISHED PRODUCTS -- EIR WAS ISSUED WITH AN INSPECTION CLASSIFICATION OF VOLUNTARY ACTION INDICATED (VAI) POST THE INSPECTION OF THE FACILITY FROM SEPT 16 TO SEPT 27, 2024

ZYDUS: ZYDUS COMPETITOR APOTEX HAS RECEIVED FINAL APPROVAL FOR THE BOTH STRENGTHS OF MIRABEGRON. BOTH 25 & 50 MG MIRABEGRON CURRENTLY ACCOUNTS FOR 8%/12% OF FY25E EARNINGS & 4%/5% OF FY26E EARNINGS FOR LUPIN/ZYDUS

LUPIN: APOTEX HAS RECEIVED A FINAL APPROVAL FOR THE MIRABEGRON

ZYDUS: APOTEX HAS RECEIVED A FINAL APPROVAL FOR THE MIRABEGRON

MANKIND PHARMA: CO SAYS REMAINING 56.31% SHARES OF BHARAT SERUMS AND VACCINES PLEDGED IN FAVOUR OF CATALYST TRUSTEESHIP

DR. REDDY’S LABORATORIES: CO UNIT DR. REDDY’S LABORATORIES INC, USA, HAS ENTERED INTO AN AGREEMENT FOR SALE OF ALL THE ISSUED AND OUTSTANDING MEMBERSHIP INTERESTS IN ITS WHOLLY OWNED SUBSIDIARY, DR. REDDY’S LABORATORIES LOUISIANA LLC (DRLL), ALONG WITH MANUFACTURING FACILITY OF DRLL IN SHREVEPORT, LOUISIANA, USA

MANKIND PHARMA LTD: RS. 88.83 CRORES NSE BLOCK TRADE; FOR ~ 305272 SHARES, AT RS. 2910.00

ALKEM LABS: CO SHALL SELL AND TRANSFER ITS UNDERTAKING BEING THE MANUFACTURING FACILITY OF THE COMPANY SITUATED AT MADHYA PRADESH FOR 1.5B RUPEES

ZYDUS LIFE: CO ANNOUNCES AGREEMENT WITH CVS CAREMARK TO ADD ZITUVIOTM, ZITUVIMETTM AND ZITUVIMETTM XR (SITAGLIPTIN / SITAGLIPTIN AND METFORMIN HYDROCHLORIDE) TO ITS TEMPLATE FORMULARY

BIOCON: JAPAN HEALTH AUTHORITY (PMDA) APPROVES BIOCON BIOLOGICS USTEKINUMAB BS, BIOSIMILAR TO J&JS STELARA

ZYDUS LIFE: SENTYNL THERAPEUTICS ANNOUNCES U.S. FDA ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR CUTX-101 (COPPER HISTIDINATE) PRODUCT CANDIDATE FOR TREATMENT OF MENKES DISEASE

CIPLA: CO TO CONSIDER Q3 RESULT ON JAN.28

LAURUS LAB: CO TO CONSIDER Q3 RESULT ON JAN.24

MANKIND PHARMA LTD: RS. 51.93 CRORES NSE BLOCK TRADE; FOR ~ 179697 SHARES, AT RS. 2890.10

BIOCON: CO UNIT BIOCON PHARMA RECEIVED APPROVAL FOR TACROLIMUS CAPSULE FROM CHINA AUTHORITY

DIVI’S LAB: CO SAYS PHASE I OF THE UNIT III GREENFIELD PROJECT AT KAKINADA, ANDHRA PRADESH, IS BEING DEVELOPED ON 200 ACRES WITH AN INVESTMENT OF ₹1,200 TO ₹1,500 CRORES

DIVI’S LAB: CO SAYS COMMENCEMENT OF COMMERCIAL OPERATIONS AT UNIT III GREENFIELD PROJECT AT KAKINADA, ANDHRA PRADESH

LUPIN LTD: Rs. 23.95 Crores NSE Block Trade; for ~ 101204 Shares, at Rs. 2366.05

SUN PHARMA: CO TO SELL 100% SHARES IN JAPAN SUBSIDIARY

CIPLA: ALBUTEROL IS 2ND LARGEST REVENUE CONTRIBUTOR TO US REVENUE OF CO

LUPIN: ALBUTEROL IS 2ND LARGEST REVENUE CONTRIBUTOR TO US REVENUE OF CO

CIPLA: GENERIC COMPETITION HAS BEEN DELAYED BY LONG TIME IN ALBUTEROL -- EMKAY SAYS AMNEALS GPROAIR IS LIKELY TO BE DELAYED

LUPIN: GENERIC COMPETITION HAS BEEN DELAYED BY LONG TIME IN ALBUTEROL -- EMKAY SAYS AMNEALS GPROAIR IS LIKELY TO BE DELAYED

LUPIN: CO ACQUIRES HUMINSULIN FROM LILLY TO ENHANCE DIABETES PORTFOLIO

TORRENT PHARMA: CO HAS ISSUED COMMERCIAL PAPERS WORTH 2B RUPEES

GRANULES INDIA LTD: Rs. 41.42 Crores NSE Block Trade; for ~ 700790 Shares, at Rs. 591.05

GLAND PHARMA: 10 OBSERVATIONS ISSUED BY ANSM INSPECTION BETWEEN DEC 9TH TO 19TH AT CENEXIS FONTENAY FACILITY

GLAND PHARMA: CO SAYS ANSM FRANCE INSPECTION AT CENEXIS FONTENAY MANUFACTURING FACILITY -- RECEIVES 10 OBSERVATIONS FROM ANSM

BIOCON: CO RECEIVED USFDA EIR WITH A VOLUNTARY ACTION INDICATED (VAI) STATUS -- THE INSPECTION AS CLOSED

BIOCON: CO SAYS THE APPROVAL IS FOR THE GENERIC VERSIONS OF VICTOZA TO TREAT TYPE-2 DIABETES AND SAXENDA USED IN THE TREATMENT OF WEIGHT MANAGEMENT

BIOCON: CO AND IT EUROPEAN PARTNER, ZENTIVA, HAVE RECEIVED A DECENTRALIZED PROCEDURE APPROVAL FOR ITS COMPLEX FORMULATION, LIRAGLUTIDE, IN THE EUROPEAN UNION

DR REDDYS LAB: CO INCORPORATES NEW WHOLLY-OWNED SUBSIDIARY IN FINLAND

DR. REDDY’S LAB: BOARD MEETING ON JAN 23 TO CONSIDER Q3 RESULTS

DIVIS LABORATORIES LTD: Rs. 44.20 Crores NSE Block Trade; for ~ 74844 Shares, at Rs. 5905.30

AUROBINDO PHARMA: CO UNIT CURATEQ BIOLOGICS RECEIVES APPROVAL FOR ONCOLOGY BIOSIMILAR BEVQOLVA FROM UK’S MHRA

LAURUS LAB: CO SAYS EIGHT ROADS VENTURES AND F-PRIME CAPITAL (“INVESTORS”) HAVE TOGETHER INVESTED RUPEES 120 CRORES IN LAURUS BIO PRIVATE LIMITED, A SUBSIDIARY OF CO

ZYDUS LIFESCIENCES LTD: Rs. 49.69 Crores NSE Block Trade; for ~ 503886 Shares, at Rs. 986.10

ZYDUS LIFE: CO RECEIVES FINAL APPROVAL FROM USFDA FOR LIDOCAINE AND PRILOCAINE CREAM USP -- LIDOCAINE AND PRILOCAINE CREAM HAD ANNUAL SALES OF USD 22M IN US

MANKIND PHARMA LTD: Rs. 21.02 Crores NSE Block Trade; for ~ 74523 Shares, at Rs. 2820.55

LUPIN: CO GOT APPROVAL FROM U.S. FDA FOR ITS ANDA FOR EMTRICITABINE, TENOFOVIR ALAFENAMIDE TABLETS 200 MG/25 MG, TO MARKET A GENERIC EQUIVALENT OF DESCOVY® TABLETS, 200 MG/25 MG OF GILEAD SCIENCES, INC. -- LUPIN IS ONE OF THE FIRST ANDA APPLICANTS AND IS ELIGIBLE FOR 180 DAYS OF SHARED GENERIC EXCLUSIVITY

GLENMARK PHARMA: CO ACQUIRES 34% STAKE IN O2 RENEWABLE ENERGY XXIV PVT LTD -- ENTITY BEING ACQUIRED BELONGS TO GENERATION AND TRANSMISSION OF SOLAR ENERGY AND OTHER SOURCES OF RENEWABLE ENERGY

IPCA LABORATORIES LTD: RS. 113.72 CRORES NSE BLOCK TRADE; FOR ~ 743560 SHARES, AT RS. 1529.40

IPCA LABORATORIES LTD: RS. 675.18 CRORES BSE BLOCK TRADE; FOR ~ 4440830 SHARES, AT RS. 1520.40

TORRENT PHARMACEUTICALS LTD: Rs. 19.38 Crores NSE Block Trade; for ~ 57033 Shares, at Rs. 3398.70

CIPLA: CITI SAYS GATTEX IS A USD 700M PRODUCT IN THE US AND IF GENERIC APPROVAL COMES THROUGH, IT COULD BE A USD 80-140M ANNUAL REVENUE PRODUCT FOR CIPLA

CIPLA: CITI NOTES SAYS GATTEX (TUDUGLUTIDE) CAN BE A BIG PRODUCT – PIPELINE VISIBILITY IMPROVES BEYOND REVLIMID

ALKEM LAB: CO & UNIT ENZENE BIOSCIENCES HAVE AGREED TO INVEST 26% EQUITY IN SUNSURE SOLARPARK FOR RENEWABLE ENERGY GENERATION, TOTALING RS. 1.95 CRORE

AUROBINDO PHARMA: CO SAYS COMPLETION OF US FDA INSPECTION AT UNIT V OF APITORIA PHARMA -- INSPECTION CLOSED WITH 2 OBSERVATIONS

GRANULES INDIA: CO ANNOUNCES FDA APPROVAL FOR ADHD TREATMENT, ADDRESSING DRUG SHORTAGES IN THE U.S.

MANKIND PHARMA: CO APPROVES RUPEES 3,000 CR FUNDRAISE VIA QIP AT FLOOR PRICE RUPEES 2,616.55/SHARE

MANKIND PHARMA: CO TO LAUNCH UP TO RS 3,000-CRORE QIP SHORTLY - MONEYCONTROL

ZYDUS LIFESCIENCES: DISINVESTMENT OF EQUITY STAKE OF MYLAB DISCOVERY SOLUTIONS -- CO UNIT ACQUIRED 6.5% STAKE IN MYLAB FOR 106 CR RUPEES

JB CHEMICALS & PHARMACEUTICALS LTD: Rs. 27.87 Crores NSE Block Trade; for ~ 150336 Shares, at Rs. 1853.65

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA LAUNCHES LACOSAMIDE ORAL SOLUTION -- THIS SOLUTIONS HAS ACHIEVED ANNUAL SALES OF APPROX USD 57M (CORRECTION)

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA LAUNCHES LACOSAMIDE ORAL SOLUTION -- THIS SOLUTIONS HAS US SALES OF USD 57M

BIOCON LTD: EMA’S CHMP RECOMMENDS APPROVAL OF BIOCON BIOLOGICS’ YESINTEK, BIOSIMILAR TO J&J’S STELARA

AUROBINDO PHARMA: CURATEQ BIOLOGICS RECEIVES POSITIVE OPINION FOR BIOSIMILAR ZEFYLTI -- EUROPEAN AGENCY ADOPTS POSITIVE OPINION FOR CURATEQS BIOSIMILAR ZEFYLTI

LUPIN: CO SAYS TRADEMARK RIGHTS TO BE TRANSFERRED TO LUPIN BY MARCH

LUPIN: CO ACQUIRES 3 TRADEMARKS FROM BOEHRINGER INGELHEIM TO STRENGTHEN DIABETES PORTFOLIO -- GIBTULIO®, GIBTULIO MET® AND AJADUO® ARE KEY COMPONENTS FOR DIABETES TREATMENT

GLENMARK PHARMA: CO ISSUED A STRING OF RECALLS FOR PILLS THAT DIDN’T DISSOLVE PROPERLY. IN ONE CASE, THE CO SAID THE PROBLEM COULD BE DEADLY

GLENMARK PHARMA: LIKELY NEGATIVE USFDA ACTION INDICATED AT KEY FACILITY

DR REDDYS: CO POSTED POOR EXPORT DATA FOR THE MONTH OF NOVEMBER

NATCO PHARMA: CO REPORTS STRONG EXPORTS DATA-- NATCO EXPORTS UP ~2X YOY

GLAND PHARMA: CO HAS RECEIVED APPROVAL FROM THE USFDA FOR PHYTONADIONE INJECTABLE EMULSION USP, 10 MG/ML SINGLE DOSE AMPULES -- CO EXPECTS TO LAUNCH THIS PRODUCT THROUGH ITS MARKETING PARTNERS IN THE NEAR FUTURE -- ACCORDING TO IQVIA, THE PRODUCT HAD US SALES OF APPROXIMATELY USD 15M FOR THE TWELVE MONTHS ENDING SEPT 2024

CIPLA: MANNKIND CORP - CENTRAL DRUGS STANDARD CONTROL ORGANISATION (CDSCO) IN INDIA HAS APPROVED AFREZZA INHALATION POWDER IN ADULTS -- MANNKIND CORP - EXPECTS TO SHIP PRODUCT FOR CIPLA BY END OF 2025 - RTRS

AUROBINDO PHARMA: CO UNIT THERANYM BIOLOGICS, CEASES TO BE A WHOLLY OWNED SUBSIDIARY FOLLOWING A 2% STAKE ALLOTMENT TO DR. SATAKARNI MAKKAPATI VIA PREFERENTIAL ISSUE

DIVIS LABORATORIES LTD: Rs. 40.38 Crores NSE Block Trade; for ~ 68322 Shares, at Rs. 5910.55

TORRENT PHARMACEUTICALS LTD: Rs. 25.41 Crores NSE Block Trade; for ~ 75067 Shares, at Rs. 3385.00

CIPLA LTD: Rs. 44.40 Crores NSE Block Trade; for ~ 303589 Shares, at Rs. 1462.60

IPCA LAB: CO RECORDS HIGHEST GROWTH AMONGST PHARMA COS AS PER NOVEMBER IPM DATA

BIOCON: CO SELLS 8M EQUITY SHARES OF SYNGENE INTERNATIONAL THROUGH BLOCK DEAL -- SHAREHOLDING IN SYNGENE NOW AT 52.46%; CO RECEIVES APPROXIMATELY 6.86B RUPEES FROM SALE

ALKEM LABS: CO SAYS NET-WORTH OF TRADE GENERIC BUSINESS OF THE CO AS ON MARCH 31, 2024, WAS ABOUT RS.519 CR -- CONSIDERATION EXPECTED TO BE UP TO RS. 750 CR

ALKEM LABS: CO GETS APPROVAL TO TRANSFER ITS TRADE GENERICS BUSINESS TO ALKEM WELLNESS

GLENMARK PHARMA: ICHNOS GLENMARK INNOVATION PRESENTS FIRST CLINICAL DATA FROM PHASE 1 STUDY OF TRISPECIFIC TREAT™ ANTIBODY, ISB 2001, SHOWING HIGH OVERALL RESPONSE RATE WITH DURABLE RESPONSES AND FAVORABLE SAFETY PROFILE IN PATIENTS WITH HEAVILY PRETREATED MULTIPLE MYELOMA

CIPLA LTD: RS. 59.57 CRORES NSE BLOCK TRADE; FOR ~ 404695 SHARES, AT RS. 1471.95

LAURUS LABS LTD: Rs. 28.80 Crores NSE Block Trade; for ~ 504239 Shares, at Rs. 571.20

BIOCON: NOVO TO CUT LIST PRICES FOR INSULIN ASPART (FIASP) BY 75% FROM 1 JAN 2026

BIOCON: CO HAS RECEIVED AN EIR WITH A VOLUNTARY ACTION INDICATED STATUS FROM US FDA, FOR OUR API FACILITY AT BENGALURU, KARNATAKA. INSPECTION CONDUCTED BY THE AGENCY BETWEEN THE 23RD TO 27TH OF SEPT

LAURUS LABS: DEAL WITH EIGHT ROADS VENTURES AND F-PRIME CAPITAL FOR INVESTMENT OF 1.2B RUPEES; SHAREHOLDING OF INVESTORS AND CO IN UNIT SHALL BE 13.73% AND 74.64%, RESPECTIVELY -- CO AND INVESTORS WILL HAVE RIGHT TO INVEST ADDITIONAL UP TO 350M RUPEES IN UNIT

LAURUS LABS: CO APPROVED INVESTMENT OF 400M RUPEES IN LAURUS BIO -- CO APPROVED EXECUTION OF AGREEMENTS WITH EIGHT ROADS VENTURES AND F-PRIME CAPITAL

TORRENT PHARMACEUTICALS LTD: Rs. 40.37 Crores NSE Block Trade; for ~ 120316 Shares, at Rs. 3355.70

AUROBINDO PHARMA LIMITED: CO US SALES IS USD 106M

AUROBINDO PHARMA LIMITED: CO UNIT WINS USFDA APPROVAL FOR PAZOPANIB TABLETS, 200 MG

DIVIS LABS: CO SAYS CAN NOT COMMENT ON PATENT LAWSUITS OF BIG PHARMA COMPANIES AND ITS IMPACT

TORRENT PHARMA: CO ENTERS INTO AN AGREEMENT WITH BOEHRINGER INGELHEIM TO ACQUIRE 3 ANTI-DIABETES BRANDS -- THE ACQUISITION FURTHER STRENGTHENS TORRENT’S EXISTING DIABETES CARE PORTFOLIO AND ITS PRESENCE IN THE ORAL ANTI DIABETIC MARKET

IPCA LABORATORIES: CO ANNOUNCES THE VOLUNTARY CLOSURE OF ITS DEFUNCT WHOLLY-OWNED SUBSIDIARY, IPCA PHARMACEUTICALS LTD SA DE CV, MEXICO, WITH NO IMPACT ON ITS BUSINESS OR FINANCIALS.

DIVIS LABORATORIES LTD: RS. 62.58 CRORES NSE BLOCK TRADE; FOR ~ 100285 SHARES, AT RS. 6240.70

AUROBINDO PHARMA: CO CLARIFIES ON THE NEWS APPEARED IN THE MEDIA ON KAKINADA SEAPORT & KAKINADA SEZ

LAURUS LABS: SETBACK FOR INDIAN CDMO SPACE -- FATE OF THE US BIOSECURE ACT WITH EACH PASSING DAY THE PROBABILITY OF BIOSECURE ACT PASSING BY THE US SENATE IS REDUCING - SALES NOTE

DIVIS LABS: SETBACK FOR INDIAN CDMO SPACE, SALES NOTE SAYS ON FATE OF THE US BIOSECURE ACT THAT IF THE BIOSECURE ACT DOESN’T CLEAR BY DEC 20 IT WOULD BE A DEAD BILL

AUROBINDO PHARMA: ANDHRA PRADESH CID BEGINS PROBE INTO ALLEGED FORCIBLE ACQUISITION BY AURBINDO PHARMA GROUP IN 2020 - SOUTH FIRST

AUROBINDO PHARMA: CO IS BIGGEST BENEFICIARY OF GRANULES SETBACK - INVESTEC REPORT

MANKIND PHARMA LTD: RS. 67.10 CRORES NSE BLOCK TRADE; FOR ~ 262309 SHARES, AT RS. 2557.95

GRANULES: GAGILLAPUR FACILITY IS CRUCIAL TO THE COMPANYS OPERATIONS, CONTRIBUTING OVER 70% OF OVERALL REVENUE AS OF THE JUNE QUARTER

GRANULES INDIA LTD: CO US FDA HAS CLASSIFIED THE INSPECTION AS “OFFICIAL ACTION INDICATED” (OAI) -- CO HAS RESPONDED TO ALL THE OBSERVATIONS ISSUED BY THE US FDA

GRANULES INDIA: CO HAS RESPONDED TO ALL THE OBSERVATIONS ISSUED BY THE US FDA

GLAND PHARMA: CO RECEIVES APPROVAL FROM THE UNITED STATES FOOD AND DRUG ADMINISTRATION (US FDA) FOR LATANOPROST OPHTHALMIC SOLUTION, 0.005% (2.5 ML

BIOCON: U.S.FDA APPROVES BIOCON BIOLOGICS’ YESINTEK™, BMAB 1200 BIOSIMILAR TO J&JS STELARA

CIPLA LTD: RS. 58.84 CRORES NSE BLOCK TRADE; FOR ~ 383555 SHARES, AT RS. 1534.15

DIVIS LABS: CITI SAYS CO MAY ENJOY ENTRESTO WINDFALL GAINS FOR MUCH LONGER THAN EARLIER EXPECTED -- CITI SAYS DIVIS LIKELY TO EVEN SUPPLY API TO COMPETITOR

DR. REDDY’S LABORATORIES: CO LAUNCHES TORIPALIMAB IN INDIA, THE FIRST AND ONLY IMMUNO-ONCOLOGY DRUG APPROVED FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA -- COMBINATION OF TORIPALIMAB AND STANDARD OF CARE CHEMOTHERAPY HAS SHOWN A 48% REDUCTION IN RISK OF PROGRESSION OR DEATH

DR REDDYS: CO LAUNCHES TORIPALIMAB IN INDIA, THE FIRST AND ONLY IMMUNO- ONCOLOGY DRUG APPROVED FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA

NATCO PHARMA: CO SELLS LAND FOR 1.16B RUPEES

CIPLA LTD: Rs. 37.78 Crores NSE Block Trade; for ~ 254629 Shares, at Rs. 1483.85

GRANULES: CO NET ZERO COMMITMENT VALIDATED AND APPROVED BY SCIENCE BASED TARGETS INITIATIVE

ZYDUS LIFE: CO EYES M&A, LICENSING TO BUILD ITS US SPECIALTY BUSINESS - ET

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA LAUNCHES TRAVOPROST OPHTHALMIC SOLUTION USP, (IONIC BUFFERED SOLUTION) -- THIS SOLUTION HAS ANNUAL SALES OF APPROX USD 66M

DR. REDDYS LABORATORIES: CO AND SENORES PHARMACEUTICALS, INC. ANNOUNCE THE LAUNCH OF IVERMECTIN TABLETS USP, 3 MG IN US MARKET

ALKEM LAB: TODAY 3PM MSCI GLOBAL INCLUSION EXPECTED IN FLOW: $201 MILLION (RS 16.68B)

NATCO PHARMA: CO SUBMITTED ANDA WITH US FDA FOR GENERIC VERSION OF EVRYSDI (RISDIPLAM) -- CO US SALES OF USD 571M

ZYDUS LIFESCIENCES: DELHI HC SETS ASIDES TEMPORARY BAN ON SALES OF SIGRIMA BY CO - NDTV PROFIT

NATCO PHARMA: CO SOLD INVESTMENT HELD IN ISCA, INC FOR $2.1M

DR. REDDY’S LABORATORIES: USFDA COMPLETED A GMP INSPECTION AT API MANUFACTURING FACILITY (CTO-2) IN BOLLARAM, HYDERABAD; INSPECTION WAS CONDUCTED FROM 13TH NOV, 2024 TO 19TH NOV, 2024 -- CO HAS BEEN ISSUED A FORM 483 WITH 7 OBSERVATIONS

ZYDUS LIFE: SC REFUSES TO GRANT INTERIM RELIEF IN BREAST CANCER DRUG CASE -- SC SENDS BACK THE CASE TO DELHI HC - CNBC TV 18

GLENMARK PHARMA: CO CFO SAYS CO TO LAUNCH THE RESPIRATORY DRUG IN NEXT 6-8 MONTHS IN US - CNBCTV18

GLENMARK PHARMA: CO CFO SAYS H2 MARGINS IS EXPECTED TO BE BETTER GIVEN THE RESPIRATORY LAUNCHES- CNBCTV1

DR REDDYS LABORATORIES LTD: Rs. 21.26 Crores NSE Block Trade; for ~ 178648 Shares, at Rs. 1190.00

GLENMARK PHARMA: Q2 EBITDA 6B RUPEES VS 4.6B (YOY) -- Q2 EBITDA MARGIN 17.70% VS 14.63% (YOY)

GLENMARK PHARMA: Q2 REVENUE 34.3B RUPEES VS 32.1B (YOY)

GLENMARK PHARMA: Q2 CONS NET PROFIT 3.5B RUPEES VS LOSS 2B (YOY); PROFIT 3.4B (QOQ)

IPCA LABORATORIES: Q2 EBITDA 4.4B RUPEES VS 3.6B (YOY) -- Q2 EBITDA MARGIN 18.7% VS 17.65% (YOY)

IPCA LABORATORIES: Q2 REVENUE 23.55B RUPEES VS 20.4B (YOY)

IPCA LABORATORIES: Q2 CONS NET PROFIT 2.3B RUPEES VS 1.45B (YOY)

ALKEM LABS: CO EXPECTS PRODUCTION TO BEGIN BY Q4 TO Q1 OF NEXT FINANCIAL YEAR, WITH NO SIGNIFICANT DELAY REPORTED AS OF NOW -- ANOTHER PRODUCT LAUNCH IS EXPECTED IN Q3, WHICH HAS RECEIVED CGT WITH VANITY DAYS EXCLUSIVITY - CONCALL UPDATE

ALKEM LABS: CO IS GUIDING FOR AN IMPROVEMENT IN EBITDA MARGINS BY AT LEAST 100 BASIS POINTS EVERY YEAR -- CO AIMS TO IMPROVE THE EBITDA MARGIN IN THE U.S. BUSINESS TO BE CLOSER TO THE OVERALL EBITDA MARGIN, WHICH IS EXPECTED TO BE AROUND 18.5% TO 19% - CONCALL UPDATE

ALKEM LABS: CO IS MAINTAINING ITS OVERALL GROWTH GUIDANCE OF AROUND 8% TO 9% FOR THE DOMESTIC MARKET -- CO EXPECTS MID-SINGLE DIGIT KIND OF GROWTH ON THE TOP-LINE - CONCALL UPDATE

CIPLA: CO SAYS USFDA HAS CONDUCTED AN INSPECTION AT THE CO’S MANUFACTURING FACILITY IN VIRGONAGAR, BENGALURU FROM 7TH - 13TH NOV 2024 -- CO SAYS ON CONCLUSION OF THE INSPECTION, CO RECEIVED 8 (EIGHT) OBSERVATIONS IN FORM 483

ALKEM LAB: H1 FY25 EBITDA MARGIN AT 21% VS FY25 GUIDANCE OF 18%

ALKEM LAB: US SALES FALL 22% VS EST 4% DECLINE

ALKEM LAB: Q2 REVENUE 34.1B RUPEES VS 34.4B (YOY)

ALKEM LAB: Q2 EBITDA 7.5B RUPEES VS 7.47B (YOY) -- Q2 EBITDA MARGIN 22.04% VS 21.71% (YOY)

ALKEM LAB: Q2 CONS NET PROFIT 6.9B RUPEES VS 6.2B (YOY)

DIVIS LAB: EXPORTS UP 41% YOY TO $73MN COMPANY HAS ONBOARDED NEW CLIENTS FOR GLP1 EXPORTS DATA SHOWS EXPORTS TO ROCHE & ALSO CORDENPHARMA

ZYDUS LIFESCIENCES: CO IS DEVELOPING A LARGE-SCALE FERMENTATION OF PROTEIN ISOLATE OF MILK, WHICH IS AN ANIMAL-FREE DERIVED MILK PROTEIN PRODUCT WITH SIGNIFICANT ESG BENEFITS. THERE ARE NEAR-TERM OPPORTUNITIES FOR MAJOR BIG LAUNCHES IN THE US OVER THE NEXT ONE TO TWO TO THREE YEARS - CONCALL UPDATE

ZYDUS LIFESCIENCES: CO EXPECTS TO MAINTAIN THE SAME R&D EXPENSE PERCENTAGE GOING FORWARD, AT LEAST FOR THE NEAR FUTURE. FY26 GUIDANCE IN THE US EXPECTS GROWTH OVER FY25, DESPITE ETHICAL COMPETITION - CONCALL UPDATE

ZYDUS LIFESCIENCES: CO PROVIDED GUIDANCE ON R&D EXPENSE, EXPECTING IT TO BE AROUND 8% OF REVENUE FOR THE FULL FY25 -- CO SAYS FY27 AND FY28 GUIDANCE IS EXPECTED TO BE "MEANINGFULLY VERY LARGE" DUE TO LARGE OPPORTUNITIES AND DAY ONE EXCLUSIVE LAUNCHES - CONCALL UPDATE

AUROBINDO PHARMA: CO SAYS EUROPEAN MEDICINES AGENCY (EMA) GRANTS GOOD MANUFACTURING PRACTICE (GMP) CERTIFICATE OF COMPLIANCE TO CURATEQ BIOSIMILARS’ MANUFACTURING FACILITY IN HYDERABAD

NATCO PHARMA: Q2 REVENUE 13.7B RUPEES VS 10.3B (YOY)

NATCO PHARMA: Q2 EBITDA 8.04B RUPEES VS 4.58B (YOY) -- Q2 EBITDA MARGIN 58.66% VS 44.41% (YOY)

NATCO PHARMA: Q2 CONS NET PROFIT 6.7B RUPEES VS 3.69B (YOY)

ZYDUS LIFESCIENCES: US FORMULATIONS SALES DE-GROWTH OF 21.9% (QOQ) AT USD 288M VS USD 371M (QOQ)

ZYDUS LIFESCIENCES: Q2 REVENUE 52.4B RUPEES VS 43.7B (YOY)

ZYDUS LIFESCIENCES: Q2 EBITDA 14.6B RUPEES VS 11.46B (YOY) -- Q2 EBITDA MARGIN 27.91% VS 26.23% (YOY)

ZYDUS LIFESCIENCES: Q2 CONS NET PROFIT 9.1B RUPEES VS 8B (YOY)

AUROBINDO PHARMA: ELARA ON CO, UPGRADE TO BUY FROM ACCUMULATE, TARGET PRICE AT RUPEES 1,568

AUROBINDO PHARMA: CO IS CONFIDENT IN ACHIEVING INTERNALLY TARGETED EBITDA MARGINS OF 21% TO 22% FOR FY 25 -- CO EXPECTS TO ACHIEVE BREAKEVEN IN THE PENICILLIN-G PRODUCT FACILITY BY Q4 FY 25 AND START CONTRIBUTING POSITIVELY FROM FY 26 ONWARDS - CONCALL UPDATE

BIOCON: USFDA CLASSIFIES BIOCON BIOLOGICS’ BIOCON PARK SITE IN BENGALURU AS VOLUNTARY ACTION INITIATED

AUROBINDO PHARMA: COS US REVENUE IN Q2FY25 INCREASED BY 2.9% YOY AND DECREASED BY 1.1% QOQ TO USD 421M, ACCOUNTING FOR 45.3% OF CONSOLIDATED REVENUE

AUROBINDO PHARMA: Q2 EBITDA 15.66B RUPEES VS 13.86B (YOY); EST 16.5B -- Q2 EBITDA MARGIN 20.1% VS 19% (YOY); EST 21%

AUROBINDO PHARMA: Q2 REVENUE 78B RUPEES VS 72.19B (YOY); EST 77.57B

AUROBINDO PHARMA: Q2 CONS NET PROFIT 8.17B RUPEES VS 7.57B (YOY); EST 9.3B

DIVIS LABS: Q2 REVENUE 23.38B RUPEES VS 19.1B (YOY); EST 22.41B

DIVIS LABS: Q2 EBITDA 7.16B RUPEES VS 4.79B (YOY); EST 6.7B -- Q2 EBITDA MARGIN 30.62% VS 25.09% (YOY); EST 30%

DIVIS LABS: Q2 CONS NET PROFIT 5.1B RUPEES VS 3.48B (YOY); EST 4.89B

GRANULES INDIA: CO UNIT V FACILITY SECURES US FDA EIR WITH NO ACTION INDICATED STATUS

LUPIN: US SALES OF USD 220M VS EST USD 232M

LUPIN: Q2 EBITDA 13.4B RUPEES VS 9.2B (YOY); EST 12.2B -- Q2 EBITDA MARGIN 23.63% VS 18.21% (YOY); EST 22%

LUPIN: Q2 REVENUE 56.7B RUPEES VS 50.4B (YOY); EST 55.65B

LUPIN: Q2 CONS NET PROFIT 8.5B RUPEES VS 4.9B (YOY); EST 7.47B - 8B (QOQ)

LAURUS LABS LTD: Rs. 35.26 Crores NSE Block Trade; for ~ 714782 Shares, at Rs. 493.25

GRANULES INDIA: CO SAYS PHASE 2 OF THE FACILITY, WITH AN ADDITIONAL 7.5B DOSE CAPACITY, IS EXPECTED TO BE COMPLETED BY Q4 FY 25, WITH VALIDATION AND COMMERCIALIZATION ACTIVITIES SLATED TO BEGIN IN Q1 FY 26 - CONCALL UPDATE

GRANULES INDIA: CO SAYS THE MARGIN WILL NOT FALL SIGNIFICANTLY IN Q3 AND Q4, AND THE CO EXPECTS TO MAINTAIN A GOOD MARGIN RUN RATE -- CO IS PREPARING FOR NEW LAUNCHES FROM THE GPI SITE, WHICH WILL HELP LOWER THE IMPACT OF THE GAGILLAPUR SLOWDOWN IN Q2 - CONCALL UPDATE

GRANULES INDIA: CO EXPECTS TO SPEND UP TO USD 2M ON A SPECIFIC INITIATIVE (RASHMI) THIS YEAR -- CO EXPECTS A MODERATE MARGIN IN Q3, WITH REVENUE INCREASING BUT MARGIN FALLING A LITTLE BIT - CONCALL UPDATE

J.B. CHEMICALS & PHARMACEUTICALS: Q2 EBITDA 2.7B RUPEES VS 2.43B (YOY) -- Q2 EBITDA MARGIN 27.04% VS 27.62% (YOY)

J.B. CHEMICALS & PHARMACEUTICALS: Q2 CONS NET PROFIT 1.74B RUPEES VS 1.51B (YOY); 1.77B (QOQ) -- Q2 REVENUE 10B RUPEES VS 8.8B (YOY)

J B CHEMICALS AND PHARMA: KKR IS SAID TO CONSIDER SELLING $750 MILLION STAKE IN JB PHARMA - BBG

GRANULES INDIA: Q2 EBITDA 2.03B RUPEES VS 2.13B (YOY) -- Q2 EBITDA MARGIN 21.04% VS 17.90% (YOY)

GRANULES INDIA: Q2 REVENUE 9.66B RUPEES VS 11.9B (YOY)

GRANULES INDIA: Q2 CONS NET PROFIT 972M RUPEES VS 1.02B (YOY)

LAURUS LABS LTD: Rs. 23.10 Crores NSE Block Trade; for ~ 468317 Shares, at Rs. 493.30

LUPIN: MACQUARIE SAYS, US GENERIC PRICING EROSION HALTING THIS COULD DRIVE A RELIEF RALLY IN US GENERIC-HEAVY NAMES SUCH AS CO AND AUROBINDO PHARMA

AUROBINDO PHARMA: MACQUARIE SAYS, US GENERIC PRICING EROSION HALTING THIS COULD DRIVE A RELIEF RALLY IN US GENERIC-HEAVY NAMES SUCH AS CO AND LUPIN

GLENMARK : ICHNOS GLENMARK INNOVATION (IGI) ANNOUNCES FIRST PRESENTATION OF DATA FROM PHASE 1 STUDY OF THE TRISPECIFIC ISB 2001 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/RMM) AT UPCOMING ASH ANNUAL MEETING

MANKIND PHARMA: CO SAYS THE ACQUISITION IS FINANCED THROUGH A MIX OF DEBT, EQUITY, AND INTERNAL ACCRUALS, WITH A POTENTIAL EQUITY RAISE TO RETIRE A PORTION OF THE DEBT AND MAINTAIN A NET DEBT TO EBITDA RATIO BELOW 2X BY FY26 - CONCALL UPDATE

MANKIND PHARMA: CO EXPECTS 15% PLUS GROWTH IN THE SECOND HALF OF THE YEAR, AND 15% TO 20% GROWTH FOR THE FULL YEAR 2026 -- CO IS MAINTAINING ITS GUIDANCE OF 25% TO 26% MARGIN FOR CO - CONCALL UPDATE

DR REDDYS LAB: EUROPEAN COMMISSION GRANTED A MARKETING AUTHORIZATION FOR RITUXIMAB BIOSIMILAR, THE COMPANYS FIRST CHMP IN EUROPE - CONCALL UPDATE

DR REDDYS LAB: CO IS WAITING FOR USFDA APPROVALS FOR A COUPLE OF PRODUCTS, HOPING TO SEE APPROVALS IN Q3, BUT NO GUARANTEE -- CO SUBMITTED A RESPONSE TO THE USFDA AND IS WAITING FOR APPROVAL, LIKELY IN THE FIRST PART OF FY 26 - CONCALL UPDATE

DR REDDYS LAB: GUIDANCE - NORMALIZED EFFECTIVE TAX RATE (ETR) IS EXPECTED TO BE AROUND 25% FOR THE FISCAL - CONCALL UPDATE

DR REDDYS LAB: GUIDANCE - SG&A SPEND IS EXPECTED TO BE IN THE RANGE OF 27.5% TO 28% FOR THE FULL FISCAL -- R&D SPEND IS EXPECTED TO BE IN THE RANGE OF 8.5% TO 9% FOR THE FULL FISCAL - CONCALL UPDATE

MANKIND PHARMA: CO SAYS APPROVED PLEDGE OF EQUITY SHARES OF UNIT BHARAT SERUMS AND VACCINES

MANKIND PHARMA: Q2 EBITDA 8.5B RUPEES VS 6.83B (YOY) -- Q2 EBITDA MARGIN 27.63% VS 25.21% (YOY)

DR. REDDYS LABORATORIES: Q2 EBITDA 20.8B RUPEES VS 19.85B (YOY); EST 21.6B -- Q2 EBITDA MARGIN 25.83% VS 29% (YOY); EST 28% (CORRECTION)

MANKIND PHARMA: Q2 REVENUE 30.8B RUPEES VS 27.1B (YOY)

MANKIND PHARMA: Q2 CONS NET PROFIT 6.5B RUPEES VS 5B (YOY); 5.4B (QOQ)

DR REDDYS: CO APPROVES FUND INFUSION VIA INVESTMENT IN SHARES OF UNIT FOR UPTO 6 BLN RUPEES

DR. REDDYS LABORATORIES: Q2 EBITDA 20.8B RUPEES VS 20.1B (YOY); EST 216B -- Q2 EBITDA MARGIN 25.83% VS 29.09% (YOY); EST 28%

DR. REDDYS LABORATORIES: Q2 REVENUE 80.3B RUPEES VS 69B (YOY); EST 77.21B

DR. REDDYS LABORATORIES: Q2 CONS NET PROFIT 12.6B RUPEES VS 14.8B (YOY); EST 14.7B - 13.9B (QOQ)

GLAND PHARMA: CO EXPECTS 1X TO 2X ASSET TURN AT CENEXI IN THE MID-TERM, DRIVEN BY COMMERCIALIZATION OF NEW CAPACITY, INCLUDING THE PFS LINE, NEW AMPOULE LINE, AND OTHER LINES - CONCALL UPDATE

GLAND PHARMA: CO EXPECTS TO RETURN TO ITS OLD 10% EBITDA LEVEL THE YEAR AFTER NEXT, ONCE ALL CAPACITY IS ON STREAM AND PIPELINE PROJECTS ARE COMMERCIALLY ONLINE. CENEXIS REVENUE IS EXPECTED TO REACH EUR 200M NEXT YEAR, REPRESENTING 0.8X GROWTH - CONCALL UPDATE

GLAND PHARMA: CO IS TARGETING TO ACHIEVE GROWTH AFTER THE NEW LINE IS UP AND RUNNING FROM JANUARY. CO EXPECTS TO BE EBITDA NEUTRAL OR LOW SINGLE-DIGIT NEXT YEAR AFTER THE NEW LINE AND ADDITIONAL CAPEX ARE COMPLETED - CONCALL UPDATE

GLAND PHARMA: CO SAYS DESPITE THESE NEAR-TERM HEADWINDS, WE CONTINUE TO STRIVE TO ACHIEVE OUR SHORT-TERM OUTLOOK: A POSITIVE EBITDA FOR Q4 OF FY25 -- WE MAINTAIN OUR GOAL OF A POSITIVE EBITDA FOR THE NEXT FISCAL YEAR, DRIVEN BY AN INCREASE IN REVENUE ABOVE THE €200 MILLION THRESHOLD - INVESTOR PRESENTATION

GLAND PHARMA: Q2 EBITDA 3B RUPEES VS 3.2B (YOY) -- Q2 EBITDA MARGIN 21.13% VS 23.60% (YOY)

GLAND PHARMA: Q2 REVENUE 14.06B RUPEES VS 13.7B (YOY)

GLAND PHARMA: Q2 CONS NET PROFIT 1.6B RUPEES VS 1.94B (YOY); 1.44B (QOQ)

TORRENT PHARMACEUTICALS LTD: RS. 63.88 CRORES NSE BLOCK TRADE; FOR ~ 201553 SHARES, AT RS. 3169.15

DR REDDYS: CO RECALLS OVER 3.3 LAKH BOTTLES OF GENERIC MEDICATION IN U.S.: USFDA - ET

CIPLA LTD: CO UPDATES REGARDING ROUTINE (CGMP) INSPECTION AT CO UNIT IN GOA BETWEEN 10TH – 21ST JUNE, 2024, USFDA HAS CLASSIFIED INSPECTION AS VOLUNTARY ACTION INDICATED

BIOCON: COS BIOSIMILARS SEGMENT REPORTED 59% TOTAL REVENUE, WHEREAS RESEARCH SERVICES CONTRIBUTED 24% AND GENERICS 17%

BIOCON: CO SAYS MAINTAIN OUTLOOK FOR TRANSITION TO ACCELERATING GROWTH IN H2 (CORRECT)

BIOCON: CO MAINTAIN OUR OUTLOOK FOR TRANSITION TO ACCELERATING GROWTH IN H2

BIOCON: Q2 EBITDA 6.85B RUPEES VS 7.4B (YOY); EST 7.4B -- Q2 EBITDA MARGIN 19.09% VS 21% (YOY); EST 20%

BIOCON: Q2 REVENUE 35.9B RUPEES VS 34.6B (YOY); EST 36.6B

BIOCON: Q2 CONS NET PROFIT 271M RUPEES VS 1.7B (YOY); EST 547M; 8.6B (QOQ)

BIOCON: BIOCON BIOLOGICS’ DRUG SUBSTANCE FACILITY IN BENGALURU CLASSIFIED AS VOLUNTARY ACTION INDICATED (VAI)

LAURUS LABS LTD: RS. 152.52 CRORES NSE BLOCK TRADE; FOR ~ 3146284 SHARES, AT RS. 484.75

TORRENT PHARMA: RS 3100.16CR BSE BLOCK TRADE; FOR ~9974777 SHARES, AT RS 3108

TORRENT PHARMA: BLOCK DEAL ALERT - PROMOTER TO SELL UPTO 2.9% STAKE VIA BLOCK DEAL -- BASE OFFER SIZE IS OF 83 LAKH SHARES OR 2.4% STAKE WORTH 2500 CR -- GREENSHOE OPTION FOR 16.5 LAKH SHARES -- OFFER FLOOR PRICE IS RS 3022.7 – 6% DISCOUNT TO CMP -- DEAL SIZE OF NEARLY RS 3000 CR - CNBC AWAAZ

CIPLA: Q2 EBITDA 18.9B RUPEES VS 17.34B (YOY); EST 18.22B -- Q2 EBITDA MARGIN 26.7% VS 25.97% (YOY); EST 26%

CIPLA: Q2 REVENUE 70.5B RUPEES VS 67B (YOY); EST 70.42B

CIPLA: Q2 CONS NET PROFIT 13B RUPEES VS 11.3B (YOY); EST 12.5B

CIPLA: UBS SAYS SUN PHARMA LAUNCH OF LANREOTIDE CAN IMPACT CIPLA -- UBS CIPLA LANREOTIDE IS VERY BIG CONTRIBUTOR AT $120-130MN , SUN TO GAIN SIGNIFICANT MARKET SHARE

AJANTA PHARMA: CO EBITDA MARGIN IS EXPECTED TO BE AROUND 28% PLUS MINUS 0.5% OR 1% FOR THE WHOLE YEAR -- US BUSINESS IS EXPECTED TO GROW AT A MID-SINGLE-DIGIT RATE FOR FY 2025 -- BRANDED GENERIC BUSINESS IS EXPECTED TO GROW AT A MID-TEENS RATE FOR FY 2025 - CONCALL UPDATE

AJANTA PHARMA: COM EXPECTS GROSS MARGIN TO REMAIN IN A SIMILAR RANGE WITH QUARTERLY MOVEMENT OF 50 BASIS POINTS TO 100 BASIS POINTS DUE TO CHANGE IN PRODUCT MIX - CONCALL UPDATE

SUN PHARMA: CO EXPECTS THE PRICING PRESSURE FROM JAPAN TO CONTINUE AFFECTING PERFORMANCE IN THE NEXT FEW QUARTERS - CONCALL UPDATE

SUN PHARMA: CO ENTERED INTO A GLOBAL LICENSING AGREEMENT FOR COMMERCIALIZING FIBROMUN, AN ANTI-CANCER IMMUNOTHERAPY, WHICH IS BEING INVESTIGATED IN REGISTRATION TRIALS FOR THE TREATMENT OF SOFT TISSUE SARCOMA AND SUBSEQUENTLY FOR GLIOBLASTOMA - CONCALL UPDATE

SUN PHARMA: CO EXPECTS ITS FY25 R&D SPEND TO BE IN THE RANGE OF 7% TO 8% OF SALES -- THE NEW GUIDANCE IS BASED ON THE COS REASSESSMENT OF THE MONEY IT WILL NEED TO SPEND DURING THE SECOND HALF OF THE YEAR - CONCALL UPDATE

DR. REDDYS LABORATORIES: CO LAUNCHES ELOBIXIBAT (BIXIBAT®) A FIRST-IN-CLASS DRUG TO TREAT CHRONIC CONSTIPATION IN INDIA

AJANTA PHARMA: CO HAS APPROVED 1ST INTERIM DIVIDEND OF RUPEES 28 PER SHARE

AJANTA PHARMA: Q2 EBITDA 3.1B RUPEES VS 2.9B (YOY) -- Q2 EBITDA MARGIN 26.22% VS 28.26% (YOY)

AJANTA PHARMA: Q2 REVENUE 11.9B RUPEES VS 10.28B (YOY)

AJANTA PHARMA: Q2 CONS NET PROFIT 2.16B RUPEES VS 1.9B (YOY); 2.45B (QOQ)

SUN PHARMA INDUSTRIES: Q2 REVENUE 133B RUPEES VS 122B (YOY); EST 133B

SUN PHARMA INDUSTRIES: US FORMULATION SALES AT US$ 517 MILLION, UP 20.3% VS EST USD 480M

SUN PHARMA INDUSTRIES: US FORMULATION SALES AT USD 517 MILLION, UP 20.3%

SUN PHARMA INDUSTRIES: Q2 EBITDA 39.4B RUPEES VS 31.8B (YOY); EST 39.6B -- Q2 EBITDA MARGIN 29.6% VS 26.08% (YOY); EST 30%

SUN PHARMA INDUSTRIES: Q2 CONS NET PROFIT 30B RUPEES VS 23.8B (YOY); EST 28.95B

SUN PHARMA: CO PRESENTS LEQSELVITM DATA HIGHLIGHTING CLINICAL EFFICACY & DURABILITY -- DATA AT 68 WEEKS OF TREATMENT WITH LEQSELVI SHOWED MEANINGFUL IMPROVEMENT IN SCALP HAIR REGROWTH

SUN PHARMA: STUDIES SHOW SUN PHARMAS WINLEVI® (CLASCOTERONE) CREAM 1% REDUCES SEBUM LEVELS AND IS SUITABLE FOR COMBINATION WITH OTHER COMMONLY USED TOPICAL ACNE MEDICATIONS - RTRS

TORRENT PHARMACEUTICALS: Q2 EBITDA 9.4B RUPEES VS 8.25B (YOY) -- Q2 EBITDA MARGIN 32.50% VS 31.02% (YOY)

TORRENT PHARMACEUTICALS: Q2 CONS NET PROFIT 4.53B RUPEES VS 3.86B (YOY); 4.57B (QOQ) -- Q2 REVENUE 28.9B RUPEES VS 26.60B (YOY)

AUROBINDO PHARMA: CO SAYS COMPLETION OF ACQUISITION OF BALANCE 49% OF EQUITY SHARES OF GLS PHARMA FOR A PURCHASE CONSIDERATION OF INR 22.5 CRORES -- GLS HAS BECOME A WHOLLY OWNED SUBSIDIARY OF THE CO

LAURUS LABS: CO EXPECTS HEALTHY GROWTH IN FY25 -- CO IS "WELL ON TRACK TO DELIVER FULL-YEAR GROWTH OUTLOOK" DRIVEN BY FACILITY RAMP-UP AND SCHEDULED CDMO PROJECT DELIVERIES IN THE SECOND HALF OF THE FINANCIAL YEAR - CONCALL UPDATE

LAURUS LABS: Q2 EBITDA 1.79B RUPEES VS 1.87B (YOY) -- Q2 EBITDA MARGIN 14.62% VS 15.34% (YOY)

LAURUS LABS: Q2 REVENUE 12.24B RUPEES VS 12.2B (YOY)

LAURUS LABS: Q2 CONS NET PROFIT 198M RUPEES VS 370M (YOY)

MANKIND PHARMA: CO COMPLETES BHARAT SERUM ACQUISITION FOR RUPEES 137.7B

ZYDUS LIFE: CO RECEIVES ACCEPTABILITY, IN PRINCIPLE, FOR ZYVAC® TCV MAKING IT ELIGIBLE FOR PURCHASE BY UNITED NATIONS PROCUREMENT AGENCIES

ZYDUS LIFE: WHO PREQUALIFIES ZYDUS’S TYPHOID VI CONJUGATE VACCINE, ZYVAC® TCV

BIOCON: AMGENS WILL LAUNCH ITS BIOSIMILAR VERSION OF REGENERONS EYECARE DRUG EYLEA -- EXPECTATION WAS OF BIOCON TO BE AMONGST THE 1ST TO LAUNCH EYLEA- CNBCTV 18

BIOCON: ANALYSTS SAYS AMGENS LAUNCH OF EYLEA MAY LEAD TO EPS CUT FOR BIOCON - CNBCTV18

GLAND PHARMA: CO TO CONSIDER Q2 RESULTS ON NOV 4

GRANULES INDIA: CO ANNOUNCES ANDA APPROVAL FOR BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS

MANKIND PHARMA: CO ISSUES SERIES OF COMMERCIAL PAPERS WORTH UPTO 30 BLN, 5 BLN, 15 BLN RUPEES

ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM USFDA FOR FLUDROCORTISONE ACETATE TABLETS USP, 0.1 MG -- FLUDROCORTISONE ACETATE TABLETS HAD ANNUAL SALES OF USD19.9M IN THE UNITED STATES (IQVIA MAT JULY 2024)

ZYDUS LIFE: EXELIXIS WINS PATENT RULING OVER MSN LABS CABOMETYX COPIES -- MSN WILL NOT BE ABLE TO LAUNCH DRUG ZYDUS WAS MSN PARTNER

ALKEM LABS: CIPLA, CO IN FINAL LAP TO BUY SAHAJANAND MEDICAL TECHNOLOGIES - ECONOMIC TIMES

LUPIN: CO LAUNCHES FIRST GENERIC OF PRED FORTE® IN THE UNITED STATES -- US SALES OF USD 198M

DR REDDYS LAB: CO SAYS 3 ADDITIONAL GROUPS OF PLAINTIFFS SOUGHT TO ADD CO AS DEFENDANT IN ALREADY PENDING LAWSUITS -- CO, OTHER DEFENDANTS TO IN RE REVLIMID ANTITRUST ACTION FILED MOTIONS TO DISMISS PLAINTIFFS LAWSUITS

ZYDUS LIFESCIENCES: CO AND ICMR INITIATE A PHASE 2 PROOF-OF-CONCEPT TRIAL OF DESIDUSTAT IN PATIENTS WITH SICKLE CELL DISEASE

IPCA LABORATORIES: Rs 164.02cr BSE Block Trade; for ~1008521 shares, at Rs 1626.3

ZYDUS: CO RECEIVED FINAL APPROVAL FROM USFDA FOR PALIPERIDONE EXTENDED-RELEASE TABLETS, 1.5 MG, 3 MG, 6 MG, AND 9 MG

ALKEM LABS: CO TO CARRY OUT CLINICAL DEVELOPMENT OF "SON-080" IN INDIA TO ENABLE REGULATORY FILING

ALKEM LABORATORIES: CO ENTERS INTO A LICENSING AGREEMENT WITH US-BASED SONNET BIOTHERAPEUTICS TO DEVELOP AND COMMERCIALISE ITS DRUG CANDIDATE FOR DIABETIC PERIPHERAL NEUROPATHY IN INDIA

BIOCON: BIOCON BIOLOGICS GLOBAL RAISES USD 800M VIA ALLOTMENT OF USD NOTES TO STRENGTHEN GLOBAL OPERATIONS

SUN PHARMA: BOARD MEETING ON OCTOBER 28 TO CONSIDER Q2 RESULTS

DR REDDYS LAB: CO SAYS DCGI GIVEN NOD TO COMMENCE PHASE 2 PART OF TRIAL

DR. REDDY’S LABS: CO SUBSIDIARY AURIGENE ONCOLOGY LTD ANNOUNCES PROMISING RESULTS OF PHASE 1 STUDY FOR INDIA’S FIRST TRIAL FOR NOVEL AUTOLOGOUS CAR-T CELL THERAPY FOR MULTIPLE MYELOMA

BIOCON: BIOCON BIOLOGICS’ COMMISSIONED REPORT HIGHLIGHTS PATHWAYS TO INCREASE ADOPTION OF BIOSIMILARS IN LMICS

NATCO PHARMA: CO AND MYLAN ARE PARTNERED ON THE DEVELOPMENT OF GENERIC OZEMPIC PRODUCTS. THE TERMS OF THE SETTLEMENT ARE CONFIDENTIAL

NATCO PHARMA: CO ANNOUNCES THAT MYLAN PHARMA INC. AND NOVO NORDISK HAVE REACHED A SETTLEMENT OF THE U.S. PATENT LITIGATION RELATED TO GENERIC OZEMPIC (SEMAGLUTIDE)

LUPIN: U.S. FDA HAS COMPLETED A PRE-APPROVAL INSPECTION OF CO BIOTECH FACILITY LOCATED IN PUNE WITH 5 OBSERVATION

BIOCON: BOARD MEETING ON OCT 30 TO CONSIDER Q2 RESULTS

BIOCON: BIOCON BIOLOGICS REFINANCES USD 1.1B (RUPEES 93,468M) LONG TERM DEBT THROUGH USD BONDS AND NEW SYNDICATED FACILITY

DR. REDDY’S LAB: CO SIGNS VOLUNTARY LICENSING AGREEMENT WITH GILEAD SCIENCES TO MANUFACTURE AND COMMERCIALISE LENACAPAVIR IN INDIA AND OTHER COUNTRIES

ZYDUS LIFESCIENCES: ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR ENZALUTAMIDE TABLETS, 40 MG AND 80 MG -- ENZALUTAMIDE TABLETS, 40 MG AND 80 MG HAD ANNUAL SALES OF USD 1417.2M IN THE UNITED STATES (IQVIA MAT JULY 2024)

MANKIND PHARMA: INDIA CCI APPROVES ACQUISITION OF BHARAT SERUMS AND VACCINES LTD BY MANKIND PHARMA

JB CHEMICALS: CO SAYS INVESTMENT REQUIRED FOR IV MANUFACTURING EXPANSION AT 494.9M RUPEES -- INVESTMENT REQUIRED FOR MANUFACTURING LINE AT 215.5M RUPEES

JB CHEMICALS: CO APPROVED CAPACITY ADDITION TO IV MANUFACTURING FACILITY AT PANOLI -- CO SAYS ESTABLISHMENT OF DEDICATED MANUFACTURING LINE FOR POVIDONE/IODINE LIQUID, OINTMENT

AUROBINDO PHARMA: CO RECEIVES USFDA APPROVAL FOR CEPHALEXIN TABLETS USP, 250 MG AND 500 MG

ZYDUS LIFE: CO RECEIVES USFDA EIR REPORT FOR TRANSDERMAL PATCH MANUFACTURING FACILITY IN AHMEDABAD, CLASSIFIED AS VAI

SUN PHARMA: CO SAYS THE TWO PARTNER COMPANIES WILL SHARE POST-COMMERCIALIZATION ECONOMICS IN ABOUT 45(PHILOGEN):55(SUN PHARMA) RATIO

SUN PHARMA: CO SAYS THE TWO PARTNER COS WILL SHARE POST-COMMERCIALIZATION ECONOMICS IN ABOUT 45 (PHILOGEN): 55 (SUN PHARMA) RATIO

SUN PHARMA: CO SAYS FIBROMUN, AN INNOVATIVE ANTI-CANCER IMMUNOTHERAPY, IS BEING INVESTIGATED IN REGISTRATION TRIALS BY PHILOGEN FOR THE TREATMENT OF SOFT TISSUE SARCOMA AND GLIOBLASTOMA

SUN PHARMA: CO AND PHILOGEN ENTER INTO A GLOBAL EXCLUSIVE COMMERCIALIZATION, LICENSE, AND SUPPLY AGREEMENT FOR COMMERCIALIZING THE SPECIALTY PRODUCT FIBROMUN

MANKIND PHARMA: CO BOARD APPROVES UP TO RS 10,000 CRORE FUNDRAISING PLAN - MONEYCONTROL

AUROBINDO PHARMA: CO SAYS COMPLETION OF US FDA INSPECTION AT UNIT II OF APITORIA PHARMA -- INSPECTION CLOSED WITH 10 OBSERVATIONS

DR REDDYS LAB: CO MADE INVESTMENT OF USD 620M IN DR. REDDY’S LABORATORIES SA, SWITZERLAND

ALKEM LABS: CO SAYS ALL PRODUCTS MANUFACTURED AT OUR SITES FOLLOW CURRENT GOOD MANUFACTURING PRACTICES -- SAMPLES OF PRODUCTS MENTIONED IN CDSCO LIST ARE SPURIOUS, NOT MANUFACTURED BY ALKEM

ALKEM LABS: CO DENIES CLAIMS OF PAN-D, CLAVAM 625 BATCHES BEING NOT-OF-STANDARD QUALITY

GLAND PHARMA LTD: RS. 100.52 CRORES NSE BLOCK TRADE; FOR ~ 564726 SHARES, AT RS. 1780.00

ZYDUS LIFE: CO AND CSIR-CENTRAL DRUG RESEARCH INSTITUTE LUCKNOW TO DEVELOP BEST-IN-CLASS DRUG FOR CHRONIC KIDNEY DISEASE INDUCED OSTEOPOROSIS

LUPIN LTD: RS. 67.70 CRORES NSE BLOCK TRADE; FOR ~ 309414 SHARES, AT RS. 2188.15

TORRENT PHARMA: CO INCORPORATED UNIT NAMELY TORRENT PHARMACEUTICALS CHILE SPA -- ENTITY BEING ACQUIRED BELONGS TO PHARMACEUTICALS SECTOR

TORRENT PHARMA: CO REFUTES CLAIMS OF SHELCAL 500 ALLEGEDLY FAILING CDSCO QUALITY TEST

SUN PHARMA: CO SAYS STUDIES ALSO CONFIRM DOSE OPTIMIZATION, WITH RESULTS DEMONSTRATING GREATER RESPONSE WITH 8 MG TABLETS TWICE-DAILY AS COMPARED TO HIGHER ONCE-DAILY DOSING

SUN PHARMA: CO PRESENTS NEW CLINICAL EFFICACY AND SAFETY DATA IN SEVERE DERMATOLOGICAL CONDITIONS AT THE 2024 EADV CONGRESS -- NEW DATA DEMONSTRATE IMPROVED HAIR SATISFACTION IN MORE THAN 95% OF PATIENTS TAKING DEURUXOLITINIB AND CLINICALLY MEANINGFUL IMPROVEMENTS IN DEPRESSION AND ANXIETY FROM BASELINE TO WEEK 24

BIOCON: CO PARTNERS WITH TABUK PHARMACEUTICALS TO COMMERCIALIZE ITS GLUCAGON-LIKE PEPTIDE-1 (GLP -1) PRODUCTS IN THE MIDDLE EAST REGION

ALKEM LABS: CENTRAL DRUGS STANDARD CONTROL ORGANISATION, HAS FLAGGED 53 DRUG SAMPLES FOR FAILING TO MEET QUALITY STANDARDS - ET NOW

ALKEM LAB: ANTACID PAN D, PARACETAMOL, GLIMEPIRIDE AMONG OVER 50 DRUGS FAIL QUALITY TEST - THE NEW INDIAN EXPRESS

CIPLA: CO PURCHASE OF 6.9124% EQUITY INTEREST OF JIANGSU XIDI PHARMACEUTICALS HELD IN CIPLA (JIANGSU) -- DEAL FOR RMB 35.8M

GLAND PHARMA LTD: Rs. 36.01 Crores NSE Block Trade; for ~ 194237 Shares, at Rs. 1853.75

JB CHEMICALS: CO FACES A DISAGREEMENT REGARDING THE VALUATION OF KKRS 54% EQUITY STAKE IN THE COMPANY, INDICATING POTENTIAL HURDLES IN NEGOTIATIONS- ETNOW

BIOCON: CO SAYS BIOCON BIOLOGICS ANNOUNCES NEW DERMATOLOGY DATA TO BE PRESENTED AT EADV CONGRESS 2024 -- A PHASE 3 STUDY SUPPORTS THE INTERCHANGEABILITY OF ADALIMUMAB AND ADALIMUMAB-FKJP, AND DEMONSTRATES BIOSIMILARITY BETWEEN BMAB 1200 AND USTEKINUMAB IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS.

GLAND PHARMA LTD: RS. 117.14 CRORES NSE BLOCK TRADE; FOR ~ 628093 SHARES, AT RS. 1865.00

GLAND PHARMA LTD: RS. 117.14 CRORES NSE BLOCK TRADE; FOR ~ 628093 SHARES, AT RS. 1865.00

GLAND PHARMA LTD: RS. 117.14 CRORES NSE BLOCK TRADE; FOR ~ 628093 SHARES, AT RS. 1865.00

LUPIN LTD: RS. 68.26 CRORES NSE BLOCK TRADE; FOR ~ 307212 SHARES, AT RS. 2222.05

IPCA LABS: BOARD MEETING SCHEDULED FOR SEPTEMBER 30 TO INTEGRATION AND CONSOLIDATION OF THE GENERICS FORMULATIONS BUSINESS IN THE US MARKET

BIOCON: CO SAYS US FDA COMPLETES INSPECTION OF BENGALURU API FACILITY WITH THREE OBSERVATIONS, NO BUSINESS IMPACT EXPECTED

GLENMARK PHARMA: CO SAYS US FDA FINDS NO OBSERVATIONS FOR MFG FACILITY IN AURANGABAD

TORRENT PHARMA: CO ISSUED COMMERCIAL PAPERS FOR 2B RUPEES

MANKIND PHARMA: CO BOARD APPROVES FUND RAISE WORTH 100B RUPEES VIA ISSUE OF NON-CONVERTIBLE DEBENTURES AND COMMERCIAL PAPERS

GLENMARK PHARMA: CO SAYS U.S. FDA HAS ISSUED FORM 483 WITH ZERO OBSERVATIONS AFTER AN INSPECTION AT THE CO’S FORMULATION MANUFACTURING FACILITY BASED OUT OF CHHATRAPATI SAMBHAJI NAGAR (AURANGABAD), BETWEEN SEPT 09 AND SEPT 20

DR. REDDY’S LABORATORIES: CO SAYS INSPECTION WAS CONDUCTED FROM 16TH SEPT TO 20TH SEPT, 2024; INSPECTION CLOSED WITH ZERO OBSERVATIONS

DR. REDDY’S LABORATORIES: CO SAYS USFDA COMPLETED A ROUTINE GOOD MANUFACTURING PRACTICE (GMP) INSPECTION AT R&D CENTRE (INTEGRATED PRODUCT DEVELOPMENT ORGANISATION OR IPDO) IN BACHUPALLY, HYDERABAD

TORRENT PHARMA: CO SAYS END OF INSPECTION, AGENCY ISSUED FORM FDA 483 WITH ONE OBSERVATION -- FORM FDA 483 WITH ONE OBSERVATION IS PROCEDURAL IN NATURE

TORRENT PHARMA: CO SAYS USFDA CONDUCTED ROUTINE GMP INSPECTION OF FORMULATION MANUFACTURING FACILITY

LUPIN: THE US COURT OF APPEALS FOR THE FEDERAL CIRCUIT HAS VACATED A US DISTRICT COURT JUDGEMENT THAT FAVORED GENERIC COMPANIES IN THE PATENT LITIGATION AROUND GMYRBETRIQ AND REMANDED THE MATTER BACK TO THE DISTRICT COURT. - ETNOW

ZYDUS LIFE: THE US COURT OF APPEALS FOR THE FEDERAL CIRCUIT HAS VACATED A US DISTRICT COURT JUDGEMENT THAT FAVORED GENERIC COMPANIES IN THE PATENT LITIGATION AROUND GMYRBETRIQ AND REMANDED THE MATTER BACK TO THE DISTRICT COURT. - ETNOW

DR REDDYS LABORATORIES LTD: RS. 205.53 CRORES NSE BLOCK TRADE; FOR ~ 316201 SHARES, AT RS. 6500.00

AUROBINDO PHARMA: PURCHASE CONSIDERATION AT 225M RUPEES

AUROBINDO PHARMA: CO ENTERED INTO A BINDING AGREEMENT WITH GLS PHARMA -- SHARES ACQUIRED AT PRICE OF 381.12 RUPEES PER SHARE

LUPIN: CO ENTERS INTO A NON-EXCLUSIVE PATENT LICENSING AGREEMENT WITH TAKEDA TOCOMMERCIALIZE VONOPRAZAN, A NOVEL GASTROINTESTINAL DRUG IN INDIA

AUROBINDO: CO UNIT EUGIA STERILES PRIVATE, RECEIVES EIR FROM US FDA

MANKIND PHARMA: BOARD MEETING ON SEPT 20 TO CONSIDER AND APPROVE RAISING OF FUNDS

BIOCON: COS BIGGEST COMPETITOR COHERUS BIOSCIENCES FACING SUPPLY DISRUPTION IN KEY PRODUCT PEGFILGRASTIM

ZYDUS LIFESCIENCES : CO APPROVED BUSINESS TRANSFER AGREEMENT TO PURCHASE API BUSINESS OF SBL, DEAL OF 84 CR RUPEES

AUROBINDO PHARMA: AURO STANDS TO GAIN THE MOST WITH 85% PRODUCT OVERLAP OPPORTUNITY SIZEGRANULES FORMULATION SALES TO US AT ~20M/MONTH, ~$250M ANNUALISED

AUROBINDO PHARMA: INVESTEC SAYS ADVERSE IMPACT FROM GRANULES GAGILLAPUR WILL CAUSE MAJOR DISRUPTION & CREATE MORE SUPPLY CHALLENGES IN THE US

DR. REDDYS LAB: CITIUS PHARMACEUTICALS - DR. REDDYS AGREED TO PARTIAL DEFERRAL WITHOUT PENALTY OF MILESTONE PAYMENT BY CITIUS ONCOLOGY INC -- CITIUS PHARMACEUTICALS INC - CO IS GUARANTOR OF OBLIGATIONS OF CITIUS ONCOLOGY, INC UNDER ASSET PURCHASE AGREEMENT - RTRS

LAURUS LABS: CO SAYS USFDA AUDIT COMPLETED TODAY FOR OUR API MANUFACTURING FACILITY AT HYDERABAD (DS-1, IKP KNOWLEDGE PARK, GENOME VALLEY, SHAMEERPET, TELANGANA) WITHOUT ANY 483 OBSERVATION

ZYDUS LIFESCIENCES: ZYDUS ANNOUNCES EXCLUSIVE LICENSING AND SUPPLY AGREEMENT FOR TWO GADOLINIUM BASED MAGNETIC RESONANCE IMAGING (MRI) INJECTABLE, CONTRAST AGENTS IN THE US -- TOTAL ADDRESSABLE MARKET OPPORTUNITY FOR GADOBUTROL INJECTION IS ESTIMATED AT US$ 120M, AND FOR GADOTERATE MEGLUMINE INJECTION AT US$ 117M IN THE US MARKET (AS PER IQVIA MAT JUL - 2024)

ALKEM LABS: CO MAY BE A BIDDER FOR JB CHEMICALS - ET

GRANULES INDIA: CO SAYS ACTIVELY ADDRESSING THE OBSERVATIONS AND ARE FULLY COMMITTED TO RESOLVING THE ISSUES RAISED. -- AND ARE FULLY COMMITTED IN RESOLVING THE ISSUES

LUPIN: CO SAYS DEAL FOR 105.5M RUPEES -- CO SAYS UPTO 42.61% STAKE IN SUNSURE SOLARPARK TO BE ACQUIRED

LUPIN: CO SIGNED SHARE SUBSCRIPTION & SHAREHOLDERS AGREEMENT WITH SUNSURE SOLARPARK SEVENTEEN -- CO TO MAKE EQUITY INVESTMENT IN SUNSURE SOLARPARK

AUROBINDO: CO GETS APPROVAL FROM USFDA FOR EUGIA STERILES PRIVATE LIMITED, A 100% STEPDOWN SUBSIDIARY.

DR REDDYS LAB: CO ISSUES CLARIFICATION ON CERTAIN ALLEGATIONS PERTAINING TO OUR ENGAGEMENT WITH AGORA ADVISORY, CO ROUTINELY ENGAGE EXTERNAL COACHES TO ENABLE SIGNIFICANT ROLE TRANSITIONS OF LEADERS.

DR REDDYS LAB: CO SAYS ANY SUGGESTION CO WAS TREATED DIFFERENTLY BY SEBI WOULD BE "BASELESS AND MALAFIDE -- CO SAYS CONTINUES TO OPERATE IN COMPLIANCE WITH ALL APPLICABLE LAWS

DR REDDYS LAB: CO SAYS FOR LIMITED PERIOD FROM OCTOBER 2020 TO APRIL 2021, WE ENGAGED SERVICES OF DHAVAL BUCH -- CO SAYS ASSIGNMENT STARTED AND ENDED WELL BEFORE MADHABI BUCHS TERM AS SEBI CHAIRPERSON

DR REDDYS LAB: CO ISSUES CLARIFICATION ON CERTAIN ALLEGATIONS PERTAINING TO OUR ENGAGEMENT WITH AGORA ADVISORY -- CO SAYS ROUTINELY ENGAGE EXTERNAL COACHES TO ENABLE SIGNIFICANT ROLE TRANSITIONS OF LEADERS

ZYDUS LIFESCIENCES: CO ANNOUNCES COMPLETION OF PHASE II(A) CLINICAL TRIAL OF USNOFLAST, A NOVEL ORAL NLRP3 INFLAMMASOME INHIBITOR IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)

MANKIND PHARMA LTD: RS. 196.28 CRORES NSE BLOCK TRADE; FOR ~ 800552 SHARES, AT RS. 2451.80

BIOCON: GST COUNCIL - GST RATE ON CANCER DRUGS REDUCED FROM 12% TO 5%; AIMED AT REDUCING THE OVERALL COST OF CANCER TREATMENT SAYS INDIA FIN MIN

CIPLA: GST COUNCIL - GST RATE ON CANCER DRUGS REDUCED FROM 12% TO 5%; AIMED AT REDUCING THE OVERALL COST OF CANCER TREATMENT SAYS INDIA FIN MIN

ZYDUS LIFESCIENCES: GST COUNCIL - GST RATE ON CANCER DRUGS REDUCED FROM 12% TO 5%; AIMED AT REDUCING THE OVERALL COST OF CANCER TREATMENT SAYS INDIA FIN MIN

CIPLA: GST COUNCIL - GST RATE ON CANCER DRUGS REDUCED FROM 12% TO 5%; AIMED AT REDUCING THE OVERALL COST OF CANCER TREATMENT SAYS INDIA FIN MIN

MANKIND PHARMA LTD: RS. 62.39 CRORES NSE BLOCK TRADE; FOR ~ 254692 SHARES, AT RS. 2449.65

SUN PHARMA: CO & MOEBIUS PLANNING FOR CONFIRMATORY PHASE 3 CLINICAL TRIALS FOR MM-II (LARGE LIPOSOMES OF DPPC AND DMPC) IS UNDERWAY

SUN PHARMA: CO & MOEBIUS ANNOUNCED THAT USFDA HAS GRANTED FAST TRACK DESIGNATION (FTD) TO MM-II FOR THE TREATMENT OF OSTEOARTHRITIS KNEE PAIN.

DR. REDDY’S LABS: CO RECEIVES USFDA EIR FOR SRIKAKULAM FACILITY, INSPECTION CLASSIFIED AS VOLUNTARY ACTION INDICATED (VAI)

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA HAS REACHED A SETTLEMENT WITH THE U.S. DEPARTMENT OF JUSTICE, AGREEING TO PAY $25 MILLION OVER FIVE YEARS WITH INTEREST, FOLLOWING THE AUGUST 2023 DEFERRED PROSECUTION AGREEMENT, WITHOUT ADMITTING ADDITIONAL LIABILITY.

LUPIN: CO LAUNCHES MIRABEGRON EXTENDED-RELEASE TABLETS IN THE UNITED STATES -- US SALES OF USD 1.6B

NATCO PHARMA: NATCO PHARMA (CANADA) INC. ANNOUNCES USD 8 MLN INVESTMENT IN EGENESIS, INC.

MANKIND PHARMA: CO HAS EXECUTED THE BUSINESS TRANSFER AGREEMENT TO TRANSFER OVER THE COUNTER (OTC) BUSINESS UNDERTAKING OF THE CO AS A GOING CONCERN ON A SLUMP SALE BASIS TO UNIT MANKIND CONSUMER PRODUCTS PVT LTD (MCPPL)

ZYDUS LIFESCIENCES: CO ISSUES CLARIFICATION REGARDING RECEIPT OF WARNING LETTER FROM USFDA SAYS AUG 30 USFDA WARNING LETTER DOESNT IMPACT EXISTING PRODUCTS MADE IN JAROD UNIT

MANKIND PHARMA LTD: RS. 73.55 CRORES NSE BLOCK TRADE; FOR ~ 301154 SHARES, AT RS. 2442.25

AUROBINDO PHARMA: CO TO STEP UP FOCUS ON BIOSIMILARS, LINES UP A SLEW OF PRODUCTS - BUSINESSLINE

BIOCON: CO SAYS THIS IS BASED ON A PRE-APPROVAL INSPECTION CONDUCTED BY THE AGENCY BETWEEN THE 10TH AND 14TH OF JUNE, 2024, AND NOW ALLOWS CO TO COMMENCE COMMERCIAL SUPPLIES FROM THIS FACILITY TO THE U.S. MARKET

BIOCON: CO HAS RECEIVED AN ESTABLISHMENT INSPECTION REPORT (EIR) FROM USFDA, FOR GREENFIELD API FACILITY (SITE 6), VISAKHAPATNAM, ANDHRA PRADESH

GLAND PHARMA LTD: RS. 176.91 CRORES NSE BLOCK TRADE; FOR ~ 961442 SHARES, AT RS. 1840.00

ZYDUS LIFESCIENCES: CO WILL TAKE ALL NECESSARY STEPS TO WORK WITH USFDA TOWARDS EARLIEST REMEDIATION OF THE ABOVE FACILITY

ZYDUS LIFESCIENCES: CO RECEIVED A WARNING LETTER ISSUED BY THE USFDA

ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM USFDA FOR SCOPOLAMINE TRANSDERMAL SYSTEM -- US SALES OF USD 70M

CIPLA: CO IN AGM SAYS CO HAVE INITIATED PROCESS OF TRANSFER OF PRODUCTS TO OTHER FACILITIES

CIPLA: CO IN AGM SAYS DOING REMEDIATION BOTH IN GOA AND INDORE FACILITIES

TORRENT PHARMA: COS INDRAD FACILITY RECEIVES USFDA EIR WITH VOLUNTARY ACTION INDICATED CLASSIFICATION, SUCCESSFULLY CLOSING THE INSPECTION

LUPIN: CO LAUNCHES DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION IN THE UNITED STATES -- DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION (RLD DOXIL® (LIPOSOMAL)) HAD AN ESTIMATED ANNUAL SALES OF USD40.9M IN THE U.S. (IQVIA MAT JUNE 2024)

NATCO PHARMA: CO GETS ANDA APPROVAL FROM USFDA FOR TABRECTA® HAS RECORDED SALES OF USD 126 MILLION

GLAND PHARMA LTD: RS. 65.12 CRORES NSE BLOCK TRADE; FOR ~ 352760 SHARES, AT RS. 1846.00

BIOCON: CO UNIT SECURES MARKET ENTRY FOR BMAB 1200, A PROPOSED BIOSIMILAR TO STELARA, IN EUROPE, UK, CANADA, AND JAPAN

DIVIS LABORATORIES LTD: RS. 88.38 CRORES NSE BLOCK TRADE; FOR ~ 180681 SHARES, AT RS. 4891.45

ZYDUS LIFE: CO RECEIVES FINAL APPROVAL FROM USFDA FOR AMANTADINE EXTENDED-RELEASE CAPSULES 68.5 MG AND TENTATIVE APPROVAL FOR 137 MG

ZYDUS LIFESCIENCES: CO SAYS THIS COULD LEAD TO A POTENTIAL COMPETITION AND IMPACT THE SALES AND PROFITS -- CO SAYS THE IMPACT OF THE SAME IS ALREADY FACTORED BY THE CO IN ITS SALES AND OPERATING PROFIT (EBITDA) EXPECTATIONS FOR FY2025

ZYDUS LIFESCIENCES: CO SAYS FURTHER, WE HAVE NOTED THAT AN APPROVAL FOR THE GENERIC PRODUCT IN THE NAME OF GASACOL HD (MESALAMINE 800 MG) OF THE CO, MARKETED IN THE UNITED STATES OF AMERICA, HAS BEEN GIVEN BY THE USFDA TO ANOTHER CO

ZYDUS LIFESCIENCES: CO ISSUES CLARIFICATION SAYS CO HAS GIVEN STATUTORY INTIMATION AND PRESS RELEASE REGARDING ACQUISITION OF 50% STAKE OF STERLING BIOTECH ON AUG 23, 2024 -- CO SAYS WE STRONGLY BELIEVE THAT TODAY’S MATERIAL PRICE MOVEMENT IN THE SHARES OF THE CO IS NOT ATTRIBUTABLE TO THIS EVENT

DR. REDDY’S LABORATORIES: CO SAYS THE INSPECTION WAS CONDUCTED FROM AUG19, 2024 TO AUG 23, 2024 -- CO SAYS WE HAVE BEEN ISSUED A FORM 483 WITH THREE OBSERVATIONS, WHICH WE WILL ADDRESS WITHIN THE STIPULATED TIMELINE

DR. REDDY’S LABORATORIES: CO SAYS USFDA TODAY COMPLETED A PRODUCT-SPECIFIC PRE-APPROVAL INSPECTION (PAI) AT OUR FORMULATIONS MANUFACTURING FACILITY (FTO SEZ PU1) IN SRIKAKULAM, ANDHRA PRADESH

SUN PHARMA: CO INTRODUCES STARIZO IN INDIA FOR ACUTE BACTERIAL SKIN, SKIN STRUCTURE INFECTIONS

SUN PHARMACEUTICAL INDUSTRIES LTD: RS. 284.42 CRORES NSE BLOCK TRADE; FOR ~ 1612832 SHARES, AT RS. 1763.50

ALKEM LABS: RS 487.23CR NSE BLOCK TRADE; FOR ~850000 SHARES, AT RS 5732.15 (PRE-OPEN)

ALKEM LABORATORIES: PROMOTER LIKELY TO SELL 0.7% STAKE (8.5 LAKH SHARES) OF ALKEM LABORATORIES VIA BLOCK DEALS -- FLOOR PRICE AT ₹5,616, AT A 3% DISCOUNT TO CMP - CNBCTV18, CITING SOURCES

SUN PHARMA: PHARMAZZ INC. AND SUN PHARMA ENTERED INTO AN AGREEMENT UNDER WHICH SUN PHARMA WILL INVEST UP TO $15M IN PHARMAZZ, INC.

GRANULES INDIA: CO RECEIVES ANDA APPROVAL FOR GLYCOPYRROLATE ORAL SOLUTION

GLENMARK PHARMA: GLENMARK THERAPEUTICS INC., USA LAUNCHES OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION USP, 0.1% (OTC)

GLENMARK PHARMA: Q1 EBITDA 5.9B RUPEES VS 4.4B (YOY) -- Q1 EBITDA MARGIN 18.13% VS 14.40% (YOY)

GLENMARK PHARMA: Q1 CONS NET PROFIT 3.4B RUPEES VS 1.50B (YOY); LOSS 12B (QOQ) -- Q1 REVENUE 32.4B RUPEES VS 30.4B (YOY)

SUN PHARMA: CO SAYS INVESTMENT RESULTING IN MORE THAN 5% HOLDING IN PHARMAZZ INC

SUN PHARMA: CO TO INVEST UPTO $15 MN INVESTMENT IN PHARMAZZ INC

IPCA LABORATORIES: Q1 EBITDA 3.92B RUPEES VS 3.07B (YOY) -- Q1 EBITDA MARGIN 18.75% VS 19.38% (YOY)

IPCA LABORATORIES: Q1 REVENUE 21B RUPEES VS 15.9B (YOY)

IPCA LABORATORIES: Q1 CONS NET PROFIT 1.92B RUPEES VS 1.63B (YOY)

CIPLA LTD: RS. 81.32 CRORES NSE BLOCK TRADE; FOR ~ 510688 SHARES, AT RS. 1592.30

NATCO PHARMA: CO DECLARED INTERIM DIVIDEND OF RS 3 PER SHARE

NATCO PHARMA: Q1 REVENUE 13.6B RUPEES VS 11.4B (YOY)

NATCO PHARMA: Q1 EBITDA 8.05B RUPEES VS 5.28B (YOY) -- Q1 EBITDA MARGIN 59.06% VS 46.30% (YOY)

NATCO PHARMA: Q1 CONS NET PROFIT 6.7B RUPEES VS 4.2B (YOY)

BIOCON: CO EXPANDS CAPACITIES TO MEET GROWING DEMAND, PLANS FUTURE INVESTMENTS FOR POST - 2030 SEMAGLUTIDE MARKET - CONCALL UPDATE

BIOCON: CO IS PLANNING NEW GENERIC FORMULATION LAUNCHES ACROSS MULTIPLE MARKETS IN THE SECOND HALF OF THE FISCAL YEAR - CONCALL UPDATE

BIOCON: CO MENTIONED THE LAUNCH OF ITS LIRAGLUTIDE FORMULATIONS FOR DIABETES AND OBESITY IN THE UK AND OTHER MARKETS WHERE PREPARATIONS ARE UNDERWAY - CONCALL UPDATE

BIOCON: CO EXPECTS A HIGH SINGLE-DIGIT KIND OF GROWTH LEVELS FOR THE BUSINESS OVERALL YEAR - CONCALL UPDATE

BIOCON: CO EXPECTS THE QUARTER ONE TRENDS TO CONTINUE INTO QUARTER TWO BEFORE SEEING A TRANSITION TOWARD ACCELERATING GROWTH ACROSS THE BUSINESSES THROUGH THE SECOND HALF OF THE FISCAL YEAR AND INTO NEXT YEAR - CONCALL UPDATE

BIOCON: COS UNDERLYING GROUP FINANCIAL PERFORMANCE, AFTER ADJUSTING FOR THE ERIS TRANSACTION, HAS COME IN LINE WITH THEIR EXPECTATIONS AND PREVIOUS GUIDANCE - CONCALL UPDATE

ZYDUS LIFESCIENCES:SARO IS EXPECTED TO BE COMMERCIALIZED IN CALENDAR YEAR 2027 -- CO PLANS TO ESTABLISH A COMMERCIALLY READY FOOTPRINT IN THE US BY THE TIME SARO IS LAUNCHED - CONCALL UPDATE

ZYDUS LIFESCIENCES: CO EXPECTS A DOUBLE-DIGIT GROWTH IN THE US, FACTORING IN THE CURRENT BASE BUSINESS AND NEW PRODUCT LAUNCHES -- CO EXPECTS AROUND 25-PLUS LAUNCHES FOR THE FULL YEAR - CONCALL UPDATE

ZYDUS LIFESCIENCES: CO EXPECTS TO DELIVER HIGH TEENS GROWTH FOR THE CURRENT YEAR -- CO EXPECTS AN IMPROVEMENT IN MARGIN BY 100 BASIS POINTS TO 150 BASIS POINTS FROM FY24 MARGINS -- CO EXPECTS AROUND AN 8% KIND OF SPEND ON R&D AND HOPES TO MAINTAIN IT - CONCALL UPDATE

ALKEM LAB: COS US SALES FOR Q1FY25 STOOD AT RS 6,416 MILLION, WITNESSING A DECLINE OF 7.7% YOY AND A GROWTH OF 2.8% ON A QOQ BASIS

ALKEM LABORATORIES: Q1 EBITDA 6.1B RUPEES VS 3.89B (YOY) -- Q1 EBITDA MARGIN 20.08% VS 13.16% (YOY)

ALKEM LABORATORIES: Q1 REVENUE 31B RUPEES VS 29.67B (YOY)

ALKEM LABORATORIES: Q1 CONS NET PROFIT 5.45B RUPEES VS 2.9B (YOY)

ZYDUS LIFESCIENCES: Q1 REVENUE 62B RUPEES VS 51.39B (YOY); 56.5B EST

ZYDUS LIFESCIENCES: Q1 EBITDA 20.84B RUPEES VS 15.05B (YOY); EST 16.35B -- Q1 EBITDA MARGIN 33.57% VS 29.3% (YOY); EST 28.9%

ZYDUS LIFESCIENCES: Q1 CONS NET PROFIT 14B RUPEES VS 11B (YOY); 11.4B EST

ZYDUS LIFE: CO RECEIVES FINAL APPROVAL FROM USFDA FOR VALBENAZINE CAPSULES -- US SALES OF USD 2B

GRANULES INDIA: CO ANNOUNCES ANDA APPROVAL FOR TRAZODONE TABLETS -- US SALES OF APPROXIMATELY $128 MILLION

BIOCON: CO HAS OTHER INCOME OF 11B IN CURRENT QUARTER RESULTS

BIOCON: Q1 EBITDA 6.2B RUPEES VS 7.14B (YOY) -- Q1 EBITDA MARGIN 18.07% VS 20.87% (YOY)

BIOCON: Q1 CONS NET PROFIT 6.6B RUPEES VS 1.01B (YOY); 1.4B (QOQ) -- Q1 REVENUE 34.3B RUPEES VS 34B (YOY)

J.B.CHEMICALS & PHARMA: Q1 EBITDA 2.7B RUPEES VS 2.32B (YOY) -- Q1 EBITDA MARGIN 28.71% VS 25.9% (YOY)

J.B.CHEMICALS & PHARMA: Q1 CONS NET PROFIT 1.7B RUPEES VS 1.42B (YOY); 1.26B (QOQ) -- Q1 REVENUE 9.5B RUPEES VS 8.5B (YOY)

LUPIN: COS GENERIC HEALTH PTY INCORPORATED LUPIN NZ

GLAND PHARMA: CO SAYS REAFFIRMED OUTLOOK - WE EXPECT POSITIVE EBITDA FOR Q4 OF THIS FISCAL YEAR AND A POSITIVE EBITDA FOR THE NEXT FISCAL YEAR, DRIVEN BY INCREASED REVENUE EXCEEDING THE €200 MILLION THRESHOLD.- INVESTOR PRESENTATION

GLAND PHARMA: CO SAYS Q2FY25 IMPACT - LOWER ACTIVITY LEVELS ARE EXPECTED DUE TO THE EUROPEAN HOLIDAY SEASON AND PLANNED SUMMER MAINTENANCE SHUTDOWNS. THE FONTENAY PLANT WILL HAVE AN EXTENDED 3-WEEK SHUTDOWN FOR NEW AMPOULE LINE INSTALLATION- INVESTOR PRESENTATION

GLAND PHARMA: CO EXPECTS TO GENERATE APPROXIMATELY EUR 10M IN REVENUE IN 2025 FROM A NEW LINE -- CO GUIDED FOR MID-TEENS YEAR-ON-YEAR GROWTH - CONCALL UPDATE

SIMPLEX CASTINGS: CO BAGS ORDER WORTH RS. 25 CR FROM SAIL

LUPIN: Q1 EBITDA 12.4B RUPEES VS 8.56B (YOY); EST 10.17B -- Q1 EBITDA MARGIN 22.16% VS 17.79% (YOY); EST 19.8%

LUPIN: Q1 CONS NET PROFIT 8B RUPEES VS 4.5B (YOY); EST 5.65B - 3.6B (QOQ) -- Q1 REVENUE 55B RUPEES VS 48.1B (YOY); EST 54.5B

AUROBINDO PHARMA: CO RECEIVES USFDA APPROVAL FOR ESTRADIOL VAGINAL INSERTS USP, 10 MCG --APPROVED PRODUCT HAS AN ESTIMATED MARKET SIZE OF US$268M FOR THE TWELVE MONTHS ENDING JUNE 2024, ACCORDING TO IQVIA

GLAND PHARMA: CO EXPECTS POSITIVE EBITDA FOR NEXT FISCAL YEAR FOR CENEXI

GLAND PHARMA: Q1 EBITDA 2.6B RUPEES VS 2.98B (YOY) -- Q1 EBITDA MARGIN 18.86% VS 25.00% (YOY)

GLAND PHARMA: Q1 CONS NET PROFIT 1.44B RUPEES VS 1.94B (YOY); 1.9B (QOQ) -- Q1 REVENUE 14B RUPEES VS 12.09B (YOY)

IPCA: CO LAUNCHES "DIULCUS IN THE INDIAN MARKET FOR TREATMENT OF DIABETIC FOOT ULCER (DFU)

LUPIN: CO GETS SHOW CAUSE NOTICE FROM MAHARASHTRA GST AUTHORITY SEEKING RECOVERY OF ₹672.4 CR OF TAX & PENALTY -- CO GETS SHOW CAUSE NOTICE FOR PERIOD JULY 2017 TO MARCH 2022

LUPIN: CO SAYS INCORPORATED LUPIN LANKA (PVY) LTD., SRI LANKA (‘LUPIN LANKA’), AS WHOLLY OWNED SUBSIDIARY OF THE CO

AUROBINDO PHARMA: CO SAYS US FDA INSPECTION AT UNIT II OF EUGIA PHARMA SPECIALITIES -- CO SAYS US FDA DETERMINED CLASSIFICATION STATUS OF FACILITY AS OFFICIAL ACTION INDICATED

BIOCON: CO HAS RECEIVED AN ESTABLISHMENT INSPECTION REPORT (EIR) WITH VOLUNTARY ACTION INDICATED (VAI) FROM THE U.S. FOOD AND DRUG ADMINISTRATION (USFDA), FOR OUR API FACILITY (SITE 5), LOCATED AT VISAKHAPATNAM, ANDHRA PRADESH

GLAND PHARMA: CO SAYS US FDA CONDUCTED UN-ANNOUNCED INSPECTION OF PASHAMYLARAM FACILITY; CONCLUSION OF US FDA UN-ANNOUNCED INSPECTION AT PASHAMYLARAM FACILITY, HYDERABAD -- CO SAYS INSPECTION WAS CONCLUDED WITH THREE (3) 483 OBSERVATIONS

AUROBINDO PHARMA: COS RS 750 CRORE BUYBACK TO OPEN ON AUGUST 5, CLOSE ON AUGUST 9

SUN PHARMA: COS US FORMULATION SALES AT USD 466M VS EST USD 518M

SUN PHARMA: COS US FORMULATION SALES AT USD 466M, LOWER BY 1%

SUN PHARMA INDUSTRIES: GLOBAL SPECIALTY SALES AT US$ 266 MILLION, EST $281M

SUN PHARMA INDUSTRIES: Q1 EBITDA 36.1B RUPEES VS 33.3B (YOY); EST 33.44B -- Q1 EBITDA MARGIN 28.51% VS 27.90% (YOY); EST 26%

SUN PHARMA INDUSTRIES: Q1 REVENUE 126.5B RUPEES VS 119.4B (YOY); EST 128.44B

SUN PHARMA INDUSTRIES: Q1 CONS NET PROFIT 28.4B RUPEES VS 20.2B (YOY); EST 25.89B

MANKIND PHARMA LTD: RS. 68.88 CRORES NSE BLOCK TRADE; FOR ~ 345740 SHARES, AT RS. 1992.25

MANKIND PHARMA: CO EXPECTS 15% TO 20% GROWTH, WITH POTENTIAL FOR EVEN BETTER PERFORMANCE -- CO TARGETS MARGINS AROUND 30% PLUS, WITH YEAR-OVER-YEAR IMPROVEMENT - CONCALL UPDATE

MANKIND PHARMA: Q1 EBITDA 6.8B RUPEES VS 6.55B (YOY)

MANKIND PHARMA: Q1 REVENUE 29B RUPEES VS 25.79B (YOY)

MANKIND PHARMA: Q1 CONS NET PROFIT 5.4B RUPEES VS 4.87B (YOY)

ZYDUS LIFE: CO RECEIVES APPROVAL FROM COFEPRIS OF MEXICO TO MARKET MAMITRA (TRASTUZUMAB BIOSIMILAR) TO TREAT VARIOUS CANCERS

DIVIS LAB: AGROCHEM & PHARMA MONTHLY DATA OUT -- MONTHLY DATA AT $39MN, INDICATING 55% (MOM) DROP & 56% (YOY) DROP

AJANTA PHARMA: CO EXPECTS OVERALL REVENUE TO GROW IN LOW TEENS IN FY 2025 -- CO EXPECTS MID-TEEN GROWTH IN BRANDED GENERICS AND DE-GROWTH IN AFRICA INSTITUTION BUSINESS IN FY 2025 - CONCALL UPDATE

GRANULES INDIA: CO IS GUIDING FOR A SIGNIFICANT IMPACT FROM THE DOMINANCE OF ITS METFORMIN PRODUCT IN THE DIABETES SEGMENT.-- CO IS ON TRACK WITH ITS CAPITAL EXPENDITURE PLANS AND EXPECTS TO BE IN LINE WITH ITS ESTIMATES AND EXPECTATIONS - CONCALL UPDATE

GRANULES INDIA: CO EXPECTS TO SEE AN IMPROVING TRAJECTORY IN ITS FINANCIAL PERFORMANCE, CO EXPECTS TO CONTRIBUTE SIGNIFICANTLY TO ITS ENTIRE PORTFOLIO FROM FY 26 ONWARDS, DRIVEN BY THE LAUNCH OF ONCOLOGY PRODUCTS - CONCALL UPDATE

DR REDDYS LAB: BARCLAYS RAISES TARGET PRICE TO $87 FROM $81

AJANTA PHARMA: Q1 REVENUE 11.5B RUPEES VS 10.21B (YOY)

AJANTA PHARMA: Q1 EBITDA 3.3B RUPEES VS 2.71B (YOY) -- Q1 EBITDA MARGIN 29% VS 26.53% (YOY)

AJANTA PHARMA: Q1 CONS NET PROFIT 2.5B RUPEES VS 2.08B (YOY)

GRANULES INDIA : CO MD SAYS Q1 PERFORMANCE HIGHLIGHTS INCLUDE CONTINUED GROWTH IN OUR FORMULATION SEGMENT, STRONG NORTH AMERICA BUSINESS, AND PRODUCT DIVERSIFICATION, WHICH OFFSET THE PARACETAMOL API/PFI DECLINE, PROMISING A BRIGHTER FUTURE DRIVEN BY OUR FORMULATIONS OFFERING AND NEW PRODUCT PIPELINE

GRANULES INDIA: Q1 EBITDA 2.59B RUPEES VS 1.37B (YOY) -- Q1 EBITDA MARGIN 21.97% VS 13.88% (YOY)

GRANULES INDIA: Q1 REVENUE 11.8B RUPEES VS 9.85B (YOY)

GRANULES INDIA: Q1 CONS NET PROFIT 1.35B RUPEES VS 479M (YOY)

MANKIND PHARMA LTD: RS. 78.13 CRORES NSE BLOCK TRADE; FOR ~ 378709 SHARES, AT RS. 2063.10

DR REDDYS: CO RECEIVES POSITIVE CHMP OPINION FROM EUROPEAN MEDICINES AGENCY FOR RITUXIMAB BIOSIMILAR

DR REDDYS LAB: CO IS INVESTING IN ITS BIOSIMILAR PRODUCTS PIPELINE DEVELOPMENT EFFORTS, INCLUDING GENERIC AND NOVEL ONCOLOGY ASSETS - CONCALL UPDATE